










The handle http://hdl.handle.net/1887/20982 holds various files of this Leiden University 
dissertation. 
 
Author: Gierman, Lobke Marijn 
Title: Inflammation : a link between metabolic syndrome and osteoarthritis? 
Issue Date: 2013-06-18 
Uitnodiging
voor het bijwonen van de openbare 
 verdediging van mijn  proefschrift getiteld:
Inflammation:  
a link between  
metabolic  syndrome  
and osteoarthritis?
De verdediging vindt plaats op
dinsdag 18 juni om 16:15 precies




Geïnteresseerden zijn van harte
welkom om het ‘lekenpraatje’ bij
te wonen om 15:15 in zaal 1 van
het academiegebouw.
 
Na afloop van de promotie is er
een receptie in Café ‘t keizertje op







Frits v.d. Ham (Frits.vanderHam@tno.nl)
Inflammation: 




ation: a link betw
een m
etabolic  syndrom




voor het bijwo en van de openbare 
 verdediging van mijn  proefschrift getiteld:
Infl mmation:  
a link between  
metabolic  syndrome  
and osteoarthritis?
D  verded ging vindt plaats op
dinsdag 18 juni om 16:15 precies




Geïnt esseerden zijn van harte
welkom om het ‘lekenpraatje’ bij
te wonen om 15:15 in z al 1 van
het academiegebouw.
 
Na afloop van de promotie is er
e n receptie in Café ‘t keizertje op






Wietske Idema (wiets84@hot ail.com)
Frits v.d. Ham (Frits.vanderHam@tno.nl)
Infla mation: 




ation: a link betw
een m
etabolic  syndrom
e and osteoarthritis?                LobKE GIERm
AN
LobKE GIERmAN




Cover Design: Annelies Wasmann
Cover Lay-out: Jeff van den Assem, www.djeph.nu
Lay-out and printing by: Gildeprint Drukkerijen, Enschede
© L.M. Gierman, 2013.
lobke.gierman@gmail.com
All rights reserved. No part of this book may be reproduced in any form without 
written permission from the author or, when appropriate, of the publishers of the 
publications.
The printing of this thesis was kindly supported by:
MRI Centrum
TNO, Metabolic Health Research
Daan Traas fonds
Nederlandse Vereniging voor Matrix Biologie
Reuma fonds
Anna Fonds




de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties







Promotor:  Prof. Dr. T.W.J. Huizinga
Co-promotor:  Dr. A.-M. Zuurmond (TNO, Leiden)
Overige leden:  Prof. Dr. P.E. Slagboom
 Prof. Dr. G.J.V.M. van Osch (Erasmus Universiteit, Rotterdam)
 Dr. P.M. van der Kraan (Radboud Universiteit, Nijmegen)
The studies presented in this thesis were performed at the Gaubius Laboratory of 
TNO, Leiden, the Netherlands. This work was financially supported by a grant from 
Dutch Top institute Pharma (project number T1-213)
Contents
Chapter 1 General introduction to osteoarthritis 7
Chapter 2 Profiling the secretion of soluble mediators by end stage  27
 osteoarthritis synovial tissue explants reveals a reduced 
 responsiveness to an inflammatory trigger
Chapter 3 Metabolic profiling reveals differences in concentrations of  47
 oxylipins and related free fatty acid precursors secreted by the
 infrapatellar fat pad of end-stage osteoarthritis and normal donors
Chapter 4 An explorative study comparing levels of soluble mediators in  73
 healthy and osteoarthritic synovial fluid
Chapter 5 Metabolic stress-induced inflammation plays a major role  85
 in the development of osteoarthritis in mice
Chapter 6 Osteoarthritis development is induced by increased dietary  107
 cholesterol and can be inhibited by atorvastatin in 
 APOE*3Leiden.CETP mice, a translational model for atherosclerosis
Chapter 7 Exploring high fat diet-induced osteoarthritis in  129
 APOE*3Leiden.CETP mice
Chapter 8 Summary and general discussion 149
Chapter 9 Nederlandse samenvatting 165
Dankwoord  175












































































General introduction to osteoarthritis
1
1.1 Introduction
In 1743 William Hunter stated; From Hippocrates to the present age it is universally 
allowed that ulcerated cartilage is a troublesome thing and that once destroyed, is 
not repaired (1). The fact that destroyed cartilage is the main feature of the disease 
osteoarthritis (OA), makes it that researchers since decades are aiming to find the 
holy grail how to interfere in the pathogenesis of OA. In general, OA is described as a 
heterogeneous joint disease characterized by a progressive loss of cartilage.
1.1.1 Facts and figures
Worldwide it is estimated that 9.6% of men and 18% of women aged >60 years have 
symptomatic OA (2). However, these numbers should be interpreted with caution 
as the definition of OA is unclear and its onset is difficult to determine. Based on 
radiographs, OA in the hand joints is most frequently followed by knee and hip (3, 
4). In general, OA is more prevalent in Europe and the USA than in other parts of 
the world (figure 1). OA is a major cause of impaired mobility and it belongs to the 
top ten of leading causes of burden of disease in high-income countries (5). In the 
Netherlands, most recent data from General Practices indicate that the prevalence of 
OA is 29/1000 for males and 50/1000 for females in the adult population (6).
1.1.2 Symptoms
Osteoarthritis is a heterogeneous disorder which is diagnosed based on symptoms, 
joint pathology or a combination of these two. Symptoms attributable to OA 
include pain, cracking (crepitus) and stiffness in the affected joints. The presence 
of osteophytes, joint space narrowing, sclerosis and altered shape of the bone end 
can be assessed, e.g. by using radiograph, and are in general classified on behalf of 
the Kellgren-Lawrence grading system (7). The most used diagnostic criteria were 
developed by the American College of Rheumatology (ACR) (8-10). These criteria 






































Several risk factors for the development and progression of OA have been determined. 
The increase of age is one of the major contributors (figure 1) and is seen in all joints. 
After the age of 50, the prevalence and incidence of OA in the female gender is 
significantly greater than in men (11). Other risk factors which are frequently shown 
to increase OA occurrence are e.g. obesity, sex hormones, ethnicity and race, genetic 
predisposition and joint trauma (12). The mechanisms by which these risk factors 
contribute to the development and progression of OA are far from understood.
Figure 1. Prevalence of osteoarthritis of the knee, by age group, sex and region in 2000 (World 
Health Organization). A regions=developed countries in North America, Western Europe, Japan, 
Australia and New Zealand. AF=countries in sub-Saharan Africa. AM BD=developing countries 
in the Americas. EM=countries in the Eastern Mediterranean and North African regions. EU 
BC=developing countries in Europe. SEA=countries in Southeast Asia. WP B=countries in the 
Western Pacific region (2).
1.1.4 Problems and challenges
Existing therapies are primarily aimed to reduce pain and no cure is available which 
can interfere in the pathology of OA. Based on different risk factors (and mechanisms 
involved) and frequently observed differences in disease progression (between 
patients but also between joints) it becomes increasingly clear that OA is a disease 
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It is hypothesized that a variety of OA forms may exist that are similar with 
respect to outcome, however have a different underlying pathophysiological process. 
This may explain the variable outcomes of clinical trials, biomarker studies and 
genetic association studies, and therefore the difficulties observed when analyzing 
the efficacy of novel drugs. Without patient stratification, clinical trials may be 
‘contaminated’ with patients that respond differently to interventions, which results 
in very large and costly clinical trials and prohibits the process of the development 
of new disease interfering therapies. To improve prediction of disease outcome, to 
optimize clinical trial efficiency and to analyze the efficacy of novel drugs, it is crucial 
to better understand the various mechanisms leading to the clinical outcome of OA.
Currently, OA management is directed toward patients in the latter phase of the 
disease. Although it is difficult to detect OA in an earlier stage, as radiographs are 
not sensitive enough, emphasis on early diagnosis and prevention could have more 
significance. Relevant biomarkers, objective measures that can be derived from 
body fluids such as blood or urine, are needed to diagnose and forecast OA in an 
earlier phase of the disease (14). To obtain representative biomarkers it is essential 
to better understand the role of local and systemic factors, which are involved in the 
pathogenesis of OA.
1.2 Local alterations; from cartilage to multiple tissue disease
OA has long been considered a wear and tear disease leading to loss of cartilage. 
During the past decades there have been significant developments in the scientific 
understanding of OA. These days OA is appreciated as a disease affecting the whole 
joint which involves complex interactions between several joint tissues (figure 2)(15, 
16).
1.2.1 Cartilage 
Articular cartilage is a highly specialized avascular connective tissue which provides 
smooth articulation and bending of the joints during movement. The extracellular 
matrix of cartilage consists mainly of collagen type II. Collagen type II provides a 





































embedded. Collagens and proteoglycans give cartilage the capacity to absorb and 
distribute loads and to present a low-friction surface (18). Chondrocytes, the only 
cell type present in cartilage, have very low metabolic activity and are assumed to 
maintain the extracellular matrix by a low turnover replacement of matrix proteins. 
During OA development the chondrocytes become “activated”, a process which is 
characterized by cell proliferation and cluster formation. A disturbed equilibrium 
develops in which the rate of loss of collagens and proteoglycans goes beyond the 
rate of the deposition of newly synthesized molecules (19).
Figure 2. Schematic overview of the normal and OA knee joint depicting the joint tissues 
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1.2.2 Synovial tissue 
Synovial tissue is in direct contact with articular cartilage and primarily maintains 
the synovial cavity and synthesizes synovial fluid. Synovial fluid has a lubricating 
function and facilitates a smooth movement between joints. Under normal 
conditions, synovial tissue consists of only 1-2 cell layers of macrophage-like (type A) 
synoviocytes and fibroblast-like (FLS or type B) synoviocytes (20). The inflammation 
of the synovium (synovitis) has been shown to occur in a number of OA patients 
and may produce proteases and cytokines that contribute to the disease (21). It has 
been suggested that activated synovial macrophages play a key role in the processes 
leading to synovial inflammation. This inflammation may act as a trigger for several 
symptoms of OA via release of soluble mediators by synovial tissue, thus contributing 
to the breakdown of cartilage by promoting destruction and impairing the ability of 
repair (22).
1.2.3 Infrapatellar fat pad
The knee joint contains a special form of adipose tissue named the infrapatellar fat 
pad (IPFP), which until recently did not receive a lot of attention as a contributor to 
the OA process. IPFP is located intra-capsularly and extra-synovially in the knee joint, 
and is in close contact with synovial layers and articular cartilage. Its main role is to 
facilitate the distribution of synovial fluid and to absorb forces through the knee (23). 
Considering its location and with regard to OA as a multiple tissue disease it is likely 
that IPFP is also involved in the pathogenesis of OA (24). Several soluble mediators 
are locally produced in the knee joint by the IPFP (25, 26). However, the precise role 
of the IPFP still needs to be elucidated.
1.2.4 Bone, meniscus and ligaments
Subchondral bone, meniscus and ligaments are described to be involved in OA 
pathogenesis. During OA, bone remodeling takes place as a result of altered joint 
homeostasis. Hereby, new bone at the joint margins (osteophytes) is formed. In 
addition, there is evidence available suggesting a link between bone sclerosis and 
modifications in bone mineralization and the progression of OA. A role for transforming 





































in the development of osteophytes (27, 28). Whether subchondral bone sclerosis 
precedes the onset of OA or is a change that occurs parallel to cartilage degradation is 
unknown (16, 29). Furthermore, a role for the meniscus and surrounding ligaments is 
proposed. Meniscal damage occurs in 63% of adults with symptomatic knee OA (30), 
and it was shown that it leads to a 7.4 times higher chance to develop radiographic 
knee OA 30 months later (31). These data suggest that bone and meniscus need to 
be incorporated in the search for new OA targets.
1.2.5 Local Inflammation
Although OA is conventionally not considered as an inflammatory disease, the 
production of several inflammatory soluble mediators by different tissues in the 
knee joint suggests that inflammation has a more important role in affecting cartilage 
homeostasis than originally thought. Until now the most studied cytokines in OA 
are interleukin (IL)-1β and tumor necrosis factor (TNF)-α. These cytokines are likely 
to be produced by articular chondrocytes, but synoviocytes may also very well be 
the source. In clinical trials attempting to block their activity, however, only minimal 
efficacy was found (32, 33). Both cytokines are mediated through the nuclear factor 
kappa B (NFκB) cascade, which is a pathway designated to have an important role in 
OA pathogenesis and a central regulator in catabolic actions in chondrocytes (34). 
Also, these cytokines are able to initiate other cytokines such as IL-8, IL-6, monocyte 
chemoattractant protein (MCP)-1 and RANTES (regulated on activation, normal 
T-cell expressed and secreted), which drive inflammation, inhibit matrix synthesis 
and promote cellular apoptosis by affecting, for example, aggrecanase (ADAMTS; 
a disintegrin and metalloproteinase with thrombospondin motifs) and collagenase 
activities (MMPs; matrix metalloproteinases) (22, 29, 35).
A special class of inflammatory mediators are oxylipins. These mediators are 
derived from fatty acids and can be found in all tissues in the body and may be 
interesting targets in relation to OA initiation and perpetuation. A balanced level of 
oxylipins is essential in maintaining joint homeostasis and alterations have widespread 
consequences. Prostaglandins are an example of such oxylipins and they have shown 
to be inhibited by non-steroidal anti-inflammatory drugs (NSAIDs), which leads to 
reduced OA pain. The precise role of other oxylipins, however, is unknown and merits 
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Exploring the role of the different oxylipins and soluble mediators involved and 
produced by several tissues in the joint, such as the synovial tissue and the IPFP, may 
lead to potential targets for disease-modifying interventions.
1.3 Systemic alterations; from mechanical to systemic disease 
For several decades OA was regarded as a joint disease complicated by mechanical 
factors and age-related modifications. Limited attention to other factors influencing 
the disease was given. With the current knowledge, it is widely accepted that OA 
is more than only a mechanical disease and may be seen as a systemic disorder of 
multifactorial origin wherein genetic, environmental, hormonal and metabolic factors 
interact and contribute to OA pathogenesis (39). The metabolic syndrome comprises 
a profile including a combination of being obese, hypertension, dyslipidemia and 
impaired glucose tolerance (40). Systemic alterations may be induced by components 
of the metabolic syndrome. Recently, various studies presented a relation between 
OA and the prevalence of metabolic syndrome. For example, it was demonstrated that 
the prevalence of metabolic syndrome is over twofold higher in the OA population 
(41). In addition, having OA is associated with an over 5 times increased risk of 
having metabolic syndrome (42). These results have led investigators to contemplate 
common underlying pathologies in OA and metabolic syndrome related diseases (39, 
43, 44).
1.3.1 Obesity 
Obesity is an important and strong risk factor for OA and one of the components of 
the metabolic syndrome (45, 46). Obesity is becoming an increasing problem in the 
western world. In the Netherlands, 11 % of the adult population is obese (body mass 
index (BMI) >30) (47). For long, it was thought that the mechanical forces induced 
by obesity could explain the association between OA and obesity. However, it has 
been demonstrated that obesity is also associated with hand OA (48). As we do not 
walk on our hands, this suggests that systemic factors induced by obesity contribute 
considerably to the initiation and progression of OA (49). Obesity is associated 





































macrophages within adipose tissue are suggested to be a metabolic link between 
obesity and OA (50). The relative contribution of these processes in the onset and 
progression of OA, however, remains unclear.
The association between obesity and the development of OA has been studied 
in several animal models. In the early 50’s it was already discovered that mice 
receiving a high fat diet (HFD) developed features of OA twice as fast compared to 
mice fed a normal diet (figure 3) (51). In addition, mice of the STR/ort strain, which 
are susceptible to develop spontaneous obesity and certain aspects of the human 
metabolic syndrome, develop OA in a short period of time (52). Furthermore, it has 
been demonstrated that mice receiving HFD showed more OA cartilage degeneration 
than those fed a normal diet in a post-traumatic mouse model (53). A very HFD in 
mice induces OA, but when animals are placed on a wheel-running exercise plan 
progression of knee OA is inhibited without reduced body fat (54). Furthermore, 
leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice, which have 
extremely high body weight on a normal diet, are protected from the development 
of OA (55), which excludes a role for mechanical factors. The fact that adipose tissue 
of mice can become inflamed under conditions of metabolic stress (e.g. HFD feeding) 
and secrete a broad spectrum of inflammatory mediators (56, 57), suggests that HFD-
fed mice constitute a suitable model to study the role of (metabolic stress-induced) 
inflammation on the development of OA.
Figure 3. Male C57/Bl6 mice receiving a high fat diet developed osteoarthritis (OA) twice as 
fast as mice receiving a control diet. The similar slopes indicate that a high fat diet accelerates 
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1.3.2 Cholesterol 
Hypercholesterolemia is associated with the metabolic syndrome. Increased levels 
of cholesterol in the plasma have shown to be associated with generalized OA (58). 
Furthermore, it has been demonstrated that genes regulating cholesterol efflux 
have a diminished expression in OA cartilage compared to normal cartilage (59). 
The underlying mechanism explaining the link between cholesterol and OA features 
are therefore very interesting. This is supported by the fact that atherosclerosis, 
which is an atheromatous vascular disease caused by elevated cholesterol intake, 
is independently associated with OA in women (60, 61). Whether atherosclerosis 
and OA have common underlying mechanisms or are causative for each other is 
uncertain.
With respect to animal models, the effects of hypercholesterolemia on OA 
development is difficult to examine, as wild type mice have a different lipoprotein 
metabolism compared to humans. The intake of a cholesterol-containing diet by wild 
type mice leads to elevated plasma cholesterol levels. However, as a result of high 
levels of anti-atherosclerotic high density lipoprotein (HDL) (‘good’ cholesterol) and 
low levels of very low (VL)DL and low (L)DL (‘bad’ cholesterol) no atherosclerosis 
develops. Experimental data on investigating the role of cholesterol, and the 
mechanism behind it in relation to OA development, are therefore scarce and more 
research needs to be done to elaborate on this association.
1.3.3 Systemic inflammation
The metabolic syndrome induces systemic inflammatory responses. This mechanism 
of action may also be held responsible for the association of metabolic syndrome 
with OA, either by a direct effect on articular cartilage, or by the modulation of 
several tissues in and around the joint. The precise role of inflammation in OA 
development is, as mentioned earlier, uncertain (chapter 1.2.4) (22, 62). Among 
the components of the metabolic syndrome, obesity was thought to be key initiator 
for OA. However, recently published epidemiologic data demonstrated that the 
metabolic syndrome rather than obesity in itself has the greatest impact on the 
severity of OA (63). OA donors showed several changed systemic mediators in 





































mediators the adipokines, such as leptin, adiponectin, resistin and visfatin, have 
been extensively studied for their pro- and anti-inflammatory capacities in OA (50). 
It is found that serum adiponectin, leptin, and resistin concentrations are associated 
with OA severity and progression and with local synovial tissue inflammation (66-68). 
The effect of adipokines on the OA process is controversial. Leptin is thought to play 
a role in TGF-β activation (69) and, as mentioned, extremely obese leptin-impaired 
mice are protected from the development of OA (55). In addition, leptin induces 
collagen release from bovine cartilage explants and upregulates MMP-1 and MMP-
13 in bovine chondrocytes (70). It has been demonstrated that adiponectin alters 
the balance by downregulating MMPs and upregulating TIMPs. However, it is also 
believed that it may act protective against OA by reducing the production of pro-
inflammatory cytokines (71). Adiponectin-treated chondrocytes produce IL-6, MMP-
3 and MMP-9 and this adipokine induces MMP-1 and IL-6 production in synovial 
fibroblasts (72, 73). A relatively newly discovered adipokine, visfatin, has been 
suggested as a promising target for treating OA. Visfatin synthesis is increased by 
IL-1β treatment in an in vitro culture of human chondrocytes. Furthermore, visfatin 
increases the synthesis and release of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 
and decreases aggrecan production in chondrocytes, suggesting a pro-inflammatory 
function in cartilage (74, 75). With regard to cholesterol, it is postulated that oxidized 
low density lipoprotein triggers pro-inflammatory cytokine production (76). It should 
be noted that these mediators are not solely originating from the blood and that 
synovial tissue (21) and IPFP (24) secrete a number of these inflammatory factors 
as well, which may contribute to OA. Whether targeting the inflammatory response 
induced by components of the metabolic syndrome, such as adipokines, will reduce 
OA development is unknown. The integration of knowledge of the metabolic 
syndrome and related diseases in OA research provides new leads to tackle the 
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1.4 Outline of the thesis
The aim of this thesis is to provide insight in the role of multiple local and systemic 
factors contributing to the pathogenesis of OA. With the current knowledge, more 
advanced technologies, and novel animal models, we should be able to shed 
a different light on the tissues involved in OA pathogenesis. Hopefully, this will 
ultimately lead to the identification of mechanisms that provide targets for disease-
modifying therapies and novel biomarkers to detect OA in an earlier phase. With 
respect to the future, we try to contribute to a rationale for a better stratification of 
OA patients and consequently to more personalized medicine.
The first three chapters include a description of local factors that possibly 
contribute to OA development. By investigating the secretion of several mediators by 
synovial tissue, IPFP and synovial fluid, a profile of OA and normal (non-OA) donors 
is provided. 
In Chapter 2 we aimed to get insight in the role of synovial tissue. We hypothesized 
that synovial tissue derived from end-stage OA patients is more inflamed than that 
from normal donors (21). The synovial tissue of OA donors may therefore secrete 
a wide array of factors that can alter cartilage degradation, which is not the case 
for synovial tissues derived from normal donors. To test this hypothesis, we used 
a multiplex approach (an advanced technology including multiplex bead-based 
immunoassays (77)). In addition, the ability of OA and normal synovial tissue to 
initiate degeneration of healthy cartilage was assessed by culturing synovial tissues 
and healthy cartilage explants in a complex in vitro co-culture transwell system.
The purpose of Chapter 3 was to explore the role of IPFP in OA. Oxylipins, 
important signaling molecules involved in the modulation of inflammatory responses 
(78, 79), were detected using a mass spectrometry method to get an overview of 
what is secreted by the IPFP. Furthermore, differences in IPFP secretion between OA 
and normal donors were evaluated.
We profiled synovial fluid samples as representatives of the secretion of soluble 
mediators by different tissues involved in the joint (Chapter 4). Again we used a 
multiplex approach to get a wide and comprehensive overview of OA and normal 






































Besides the involvement of local factors we examined the development of OA 
with regard to alterations on a systemic level. Considering the hypothesis that obesity 
might lead to metabolic stress, which possibly contributes to the development of 
OA (62), we used a HFD-induced OA mouse model which is described in Chapter 5. 
More specifically, we used the human C-reactive protein (hCRP) transgenic mice (80). 
CRP is an acute phase protein and an established marker for systemic inflammation 
in humans (81). Consequently, we were able to monitor the inflammatory state of 
the animals, using a human marker, during the development of OA. To perceive 
whether medicines applied for other targets in the metabolic syndrome were able to 
counteract OA-related changes, we included a prophylactic intervention with statins 
(cholesterol-lowering drug) and a peroxisome proliferator activated receptor (PPAR) 
agonist (anti-diabetic drug).
In Chapter 6 we emphasized on lipid and systemic alterations induced by elevated 
cholesterol intake instead of HFD. We investigated whether a cholesterol-containing 
diet and, consequently, the development of atherosclerosis was sufficient to induce 
OA in APOE*3 Leiden.CETP transgenic mice. This is a well-established model for 
hyperlipidemia and atherosclerosis and resembles the human lipoprotein metabolism 
in contrary to wild type mice (82-84). Furthermore, we included cholesterol-lowering 
interventions, with a statin and ezetimibe, in groups receiving a high cholesterol diet, 
to assess their effects on OA development. Both drugs diminish cholesterol levels to 
a same extent but have a different mode of action, which allowed us to investigate 
possible additional effects of statin beyond its cholesterol-lowering capacities.
To elaborate more on the outcomes of chapters 5 and 6, in Chapter 7 we 
extrapolated the HFD-induced OA mouse model to the APOE*3 Leiden.CETP mouse. 
We included an early (‘prophylactic’) and late (‘therapeutic’) intervention with a statin. 
Furthermore, we included a fenofibrate (cholesterol-lowering drug) intervention, 
since another study indicated that this type of drug has beneficial effects on OA 
development. To gain more insight into the mechanisms behind the HFD-induced 
OA model, the effect of a caspase-1 inhibitor, responsible for the conversion of pro-
IL-1 to IL-1 (one of the key cytokines believed to be involved in OA), was studied. In 
addition, a group that started on HFD, but returned to control chow diet halfway the 




































General introduction to osteoarthritis
1
In the final chapters, Chapter 8 and Chapter 9 (in Dutch), a comprehensive 
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Objective: Evidence is accumulating that synovial tissue plays an active role in 
osteoarthritis (OA), however, exact understanding of its contribution is lacking. 
In order to further elucidate its role in the OA process, we aimed to identify the 
secretion pattern of soluble mediators by synovial tissue and to assess its ability to 
initiate cartilage degeneration.
Methods: Synovial tissue explants (STEs) obtained from donors without history of 
OA (n=8) or from end stage OA patients (n=16) were cultured alone or together with 
bovine cartilage explants in the absence or presence of IL-1α. The secretion of 48 
soluble mediators was measured and the effect on glycosaminoglycan (GAG) release 
and matrix metalloproteinase (MMP) activity was determined.
Results: Normal and OA STEs secreted comparable levels of almost all measured 
soluble mediators. However, in the presence of IL-1α these mediators were less 
secreted by OA than by normal STEs of which 15 differed significantly (p<0.01). No 
effect of normal or OA STEs on GAG release from the cartilage explants was observed, 
and no differences in MMP activity between OA and normal STEs were detected.
Conclusions: Unexpectedly, a comparable secretion profile of soluble mediators was 
found for OA and normal STEs while the reduced responsiveness of OA STEs to an 
inflammatory trigger indicates a different state of this tissue in OA patients. The 
effects could be the result of prolonged exposure to an inflammatory environment in 
OA development. Further understanding of the pro-inflammatory and inflammation 
resolving mechanisms during disease progression in synovial tissue may provide 




































Secretion of soluble mediators by synovial tissue
2
Osteoarthritis (OA) is one of the most frequently occurring rheumatic diseases. In 
Western populations OA is by far the most common form of joint disease, causing 
pain, loss of function and disability (1). The main characteristic of the disease is 
progressive loss of articular cartilage, which is thought to be due to an imbalanced 
interplay between anabolic, anti-catabolic, anti- and pro-inflammatory and anti- and 
pro-apoptotic activities (2, 3). Numerous risk factors for OA have been identified, 
however, the exact etiology, pathogenesis and progression of this disease have yet 
to be determined (4). As a consequence of the limited understanding of the disease 
complexity, no disease modifying treatments are currently available. The only 
existing therapeutic strategies are primarily aimed at reducing pain and improving 
joint function.
Traditionally, research on knee OA has been focused on cartilage degradation. 
Nowadays, however, it is generally accepted that the entire joint organ including 
synovium, synovial fluid, bone and infrapatellar fat pad can contribute to the disease 
(5). Inflammation, classically seen as a characteristic for rheumatoid arthritis (RA), 
has lately also been recognized for its role in OA development (6, 7). Inflammation of 
the synovium (synovitis) has been shown to occur in a number of knee OA patients (8) 
and may produce proteases and cytokines that contribute to the disease. However, 
its role in the onset and progression in OA has yet to be elucidated. 
It has been suggested that activated synovial macrophages might play a key role 
in the processes leading to synovial inflammation. This inflammation may act as a 
trigger for several symptoms of OA via release of soluble mediators by synovium, thus 
contributing to the breakdown of cartilage by promoting destruction and impairing 
the ability of repair (6). The cytokines interleukin (IL)-1β and tumor necrosis factor 
(TNF)-α are likely to be one of those soluble mediators (9). The understanding of the 
role of synovium and inflammation in the process of OA development could provide 
leads for new targets for OA treatment. 
Based on published literature we hypothesized that synovium from OA patients 
is more inflamed than synovium of normal donors and therefore plays an active role 
in the breakdown of cartilage. To provide insight in this hypothesis, synovial tissue 
explants (STEs) of normal donors and OA patients were collected and analyzed for 





































inflammatory trigger which was expected to be more increased in OA STEs than in 
normal STEs. We also used a complex in vitro co-culture model in which STEs were 
cultured together with cartilage explants in a Transwell system to assess the ability of 
STEs to initiate degeneration of healthy cartilage. 
Methods
STEs collection
Synovium of the knee was obtained from post-mortem material of 8 donors with 
macroscopically healthy cartilage and no history of OA (normal STE), or from material 
obtained during joint replacement surgery of 16 OA patients (OA STE) (Articular 
Engineering, Northbrook, USA). Human tissues were obtained according to legal and 
ethical requirements approved by the institutional review board of the University 
of Pennsylvania including anonymous informed written consent from the donor 
or nearest relative. Normal donors’ age ranged from 18 – 67 years and body mass 
index (BMI) from 19 – 37. OA donors’ age ranged from 43 – 70 and BMI from 18 
– 47. Within 24 hours, synovial tissue was carefully excised from surrounding fat. 
Explants of 3 mm in size and a weight of 22 ± 3.5 mg were placed in a 48-wells plate 
in Iscove’s Modified Dulbecco’s Medium (IMDM, Invitrogen, Paisley, UK) containing 
10% v/v fetal calf serum (FBS) (GibcoBRL, Invitrogen) and 1% v/v of 10,000 units/ml 
Penicillin:10,000 units/ml streptomycin (Penstrep) (Biowhittaker, Verviers, Belgium). 
STEs were placed at 4°C until the start of the experiment. STEs were placed for 1 
hour at 37°C in a humidified atmosphere of 5% CO2 in air before the start of the 
experiment.
Immunohistochemistry of STEs 
From each donor one STE was directly frozen in Tissue Tek O.C.T. compound (Sakura 
Finetek, Zoeterwoude, the Netherlands) and cut into 5 μm slices using a cryotome. 
Samples were thawed for 30 minutes and blocked with PBS containing 5% bovine 
serum albumin (BSA) (Sigma-Aldrich, St. Louis, USA). Sections were incubated 
overnight at 4°C with antibody CD68-biotin (mouse IgG2b 1:750) (E-bioscience, San 
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with peroxidase (Dako, Heverlee, Belgium). After a final wash step in PBS, sections 
were incubated with Novared for 10 minutes and counterstained with heamatoxylin. 
As a negative control an isotype matched control antibody was used (IgG2b-biotin, 
BD).
STEs culture
As a reflection of the whole synovium, for each condition 6 STEs from different 
anatomical locations in the joint per donor were cultured in a 24 wells plate in 700 
µl Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 
Insulin-transferrin-sodium selenite (ITS) (Roche Diagnostics, Basel, Switzerland), 1% 
v/v Penstrep, 1 mg/ml lactalbumin and 5 µg/ml vitamin C (Sigma-Aldrich) (serum 
free medium) and were incubated with or without 10 ng/ml IL-1α (Peprotech, Rocky 
Hill, USA). After 3 and 5 days 350 µl medium was refreshed and stored. After 7 days 
all medium was collected. Pooled supernatant samples were made representing the 
average of 6 different STEs per donor and the production over a time period of 7 
days. All samples were stored at -80 °C.
Multiplex ELISA assay
By using 2 commercial kits (42- human cytokine-plex and 11-human adipokine-plex, 
catalogue number: MPXHCYTO60KPMX42 and HADCYT-61K-11, Millipore, Billerica, 
USA) a wide panel of soluble mediators was measured in pooled supernatants of the 
STEs cultured alone. These assays were performed with Luminex xMap Technology 
(Qiagen, Billerica, USA) according to the manufacturer’s instructions. Liquichip 
analyzer software (Qiagen) was used for data analysis.
Preparation of cartilage explants
Due to the availability and heterogeneity of human cartilage explants, standardization 
for in vitro models is difficult and therefore we used bovine cartilage explants (10-
12). Cartilage from the metacarpophanlangeal joints of 6 months old calves was 
obtained on the day of slaughter. Permission of the slaughterhouse (Ton Boer en zn., 
Nieuwerkerk a/d IJssel, the Netherlands) to use these joints in this experiment was 





































a biopsy punch of 4 mm. The cartilage explants were cultured in serum free medium 
overnight at 37°C in a humidified atmosphere of 5% CO2 in air.
STE-cartilage co-culture
Co-culturing of cartilage explants and STEs was performed in a 24-wells polycarbonate 
Transwell system with a pore size of 0.4 µm (Corning Incorporated, NY, USA). Each 
well contained a cartilage punch in the lower compartment and a STE in the upper 
compartment in 700 µl serum free medium with or without 10 ng/ml human IL-
1α. Six STEs per donor per condition were used. As a control, cartilage was cultured 
alone. After 3 and 5 days 350 µl medium was refreshed and stored. After 7 days all 
medium was collected. Pooled supernatant samples were made representing the 
average of 6 different STEs per donor and the production over a time period of 7 
days. All samples were stored at -80°C.
Analysis of glycosaminoglycans (GAGs)
Cartilage explants were digested 24 hours at 56°C in 3% v/v papain from papaya 
latex, 5 mM cysteine HCL, 50 mM EDTA, and 0.1 M sodium acetate (pH 5.53) (Sigma-
Aldrich). The amount of glycosaminoglycans (GAGs), reflecting the amount of 
proteoglycans, was determined in cartilage explants as well as in culture medium 
using a commercial kit (Biocolor Ltd, Belfast, N. Ireland). The total GAG content was 
calculated by summing the amount of GAGs in the cartilage explant and the culture 
medium. Proteoglycan degradation was expressed as the percentage of GAG release 
into the medium compared to the total GAG content. 
Analysis of matrix metalloproteinase (MMP) activity
Secreted MMP activity was assessed in the culture medium using a fluorogenic 
substrate as described previously (13). The secreted MMP activity was calculated 
by determining the difference in substrate conversion in the presence or absence of 
MMP inhibitor BB94 (10 µM). This approach detects only MMP-mediated substrate 
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Data analysis 
Statistical analyses were performed using SPSS software version 17.0. Individual 
differences were tested by non-parametric Mann-Whitney tests. For comparisons 
of normal and OA STEs in the co-culture conditions, the GAG release of the cartilage 
explants were subtracted from the co-culture condition to correct for differences 
in bovine donors (D). Differences were considered statistically significant at p<0.01 
for the Multiplex Elisa data. This cut-off was chosen to reduce the chance of false-
positives, since a large number of variables were tested in a relative small number 
of donors due to the uniqueness of this material. For GAG release and MMP activity 
significance levels were set at p<0.05.
Results
Secretion of soluble mediators by STEs
To assess differences between normal and OA STEs 48 soluble mediators were 
measured in the pooled supernatants. Without IL-1α stimulation, only 5 soluble 
mediators were secreted at significantly different levels (p<0.01). Remarkably, these 
mediators were excreted at a lower level by OA STEs than normal STEs (Figure 1A).
Under pro-inflammatory (IL-1α-stimulated) conditions 15 of the measured mediators 
were significantly less secreted by OA STEs than by normal STEs (p<0.01). Of these 15 
mediators, 4 were also significantly different in the absence of IL-1α (Figure 1B). IL-
13, IL-17, IL-2, IL-4, IL-9, PDGF-AB, TGFα, TNF-β and IL-12p70 could not be detected 
in either condition.
To assess the response to an inflammatory trigger of STEs from normal and OA 
donors, soluble mediator excretion levels were analyzed in both the non-stimulated 
and the IL-1α-stimulated condition. For normal STEs, 16 mediators increased 
significantly (p<0.01) after stimulation with IL-1α (Figure 2A). Unexpectedly, the STEs 
obtained from OA donors secreted only 3 mediators at a significantly different level 
after IL-1α stimulation (Figure 2B). An overview of all measured mediators in these 





































Figure 1. Soluble mediator secretion by normal and OA synovial tissue explants (STEs) with 
or without IL-1α. Graphs demonstrate all soluble mediators which were significantly (p<0.01) 
different between A. normal (black bars) and OA (grey bars) STEs and B. normal and OA STEs 
under pro-inflammatory (IL-1α) conditions. Data were obtained from pooled supernatants 
representing the average of 6 STEs per donor and the production in a time period of 7 days. 
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Figure 2. Soluble mediator secretion by non-stimulated and stimulated synovial tissue 
explants (STEs) from normal and OA donors. Graphs demonstrate the absolute levels of all 
soluble mediators, which were significantly (p<0.01) different between A. non-stimulated 
(black bars) and IL-1α-stimulated (white bars) normal STEs and B. non-stimulated (grey bars) 
and IL-1α-stimulated (white bars) OA STEs. Data were obtained from pooled supernatants 
representing the average of 6 STEs per donor and the production in a time period of 7 days. 






































Immunohistochemistry on one STE from each donor showed well known 
characteristics of OA such as hyperplasia as observed by an increase in cell number 
and thickening of the synovial layer. CD68+ cells were present in both OA and normal 
STEs, indicating the presence of synovial macrophages during the culture period 
(Figure S1).
Co-culture effects on GAG-release and MMP-activity in cartilage explants
Based on multiplex analysis we questioned if there was also a different effect of 
normal and OA STEs on cartilage degradation. Hereto, we used an in vitro co-culture 
model in which cartilage explants were cultured together with STEs. Co-culturing with 
normal or OA STEs did not induce additional GAG release above the basal release 
of cartilage explants in non- and IL-1α-stimulated culture conditions (Figure 3). IL-
1α stimulation led to significantly more GAG release in all culture conditions (table 
1). When comparing absolute values, normal and OA donors differed significantly, 
however, this was due to a significant difference in basal release of the cartilage 
explants and not for additional GAG release induced by STEs (indicated in table 1 by 
the calculated delta (Δ)). 
Table 1. Percentage GAG release from cartilage explants cultured alone or together with STEs 
under non-stimulated and IL-1a-stimulated conditions. 


































0.002 0.000 0.245 0.032










0.180 0.576 0.245 0.267
%GAG release is indicated as mean (SD).
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Figure 3. Proteoglycan degradation of healthy cartilage explants cultured alone or together 
with synovial tissue explants (STEs). Proteoglycan degradation was expressed as the 
percentage of glycosaminoglycans (GAG) released into the medium during 7 days of culture of 
cartilage alone or co-cultured together with normal (A, B) or OA (C, D) STEs without (A, C) or 
with (B, D) IL-1α stimulation. Each line represents an individual donor and connects the % GAG 
release of cartilage alone (left) with the matching co-culture condition of cartilage together 
with STEs (right). There were no significant differences between cartilage cultured alone or 
co-cultured with normal or OA STEs.
To assess for collagen degrading enzymes, MMP activity was measured in the 
different culture conditions. Remarkably, the MMP activity in the medium of non-
stimulated normal and OA STEs cultured alone was significantly higher than in the 
co-cultures (p<0.01, Figure 4A,C). This was also observed for the IL-1α-stimulated OA 
condition (Figure 4D; p<0.05). A trend was observed in the IL-1α-stimulated normal 
condition (Figure 4B; p<0.1). IL-1α stimulation did not led to significantly more MMP 





































significantly more MMP activity in the co-cultures with OA STE while this was not the 
case for normal STE culture conditions. This is probably due to the fact that bovine 
cartilage donors used in the OA STE conditions were more prone to IL-1α stimulation 
with respect to MMP activity than those used in normal STE conditions (table 2).
Figure 4. Secreted MMP activity of STEs and cartilage explants cultured alone or together. 
After 7 days, the MMP-activity (rfu/sec) was determined (in culture medium) of normal (A, B) 
and OA (C, D) STEs and healthy cartilage explants, cultured alone or together, without (A, C) or 
with (B, D) IL-1α stimulation. Each line represents an individual donor and demonstrates the 
activity of STEs alone (left), STEs together with cartilage explants (middle) or cartilage explants 
cultured alone (right). The MMP activity in the medium of STEs cultured alone was higher, 
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Table 2. Secreted MMP activity (rfu/sec) by STE and cartilage alone and by the co-culture of 
STE and cartilage under non-stimulated and Il-1a-stimulated conditions. 











































0.174 0.004 0.121 0.061
Secreted MMP activity is indicated as mean (SD) 
Discussion
Increasing evidence indicates that inflammation of the synovium is a feature of OA 
associated with the progression of disease (6). It remains, however, unclear in which 
way alterations in the synovium contribute to degenerative processes in the cartilage. 
By measuring the secretion of soluble mediators by the synovium and investigate its 
effect on cartilage break-down, we hoped to identify new mechanisms in OA and to 
provide new targets to intervene in the disease process. Unexpectedly, STEs from 
end stage OA patients showed comparable secretion levels as normal STEs for a 
wide panel of soluble mediators, suggesting that the inflammatory state of end stage 
OA-derived synovium is not different from normal. Differences between normal 
and end-stage OA STEs appeared after stimulation with IL-1α showing a diminished 
responsiveness of OA compared to normal STEs. Furthermore, STEs derived from end 
stage OA patients did not induce more GAG release from healthy cartilage explants 
or displayed more MMP activity than normal STEs in the presence or absence of a 
pro-inflammatory trigger. This suggests that synovium from end stage OA patients is 
not, or no longer capable of initiating cartilage degradation.
With regard to OA, the pro-inflammatory cytokines IL-1β and TNFα are most 
frequently studied and detected. Furthermore IFN-γ, IL-2, IL-4, IL-6, IL-8, TGFβ and 
IL-10 have received attention as important cytokines in the OA process (14-17). Of 





































1α, one of the key cytokines in the pathogenesis of OA (18), was significantly less 
secreted by end stage OA STEs than by normal STEs.
The unexpected effects in mediator release and on GAG release seen in our study 
could be explained by the state of the STEs. All OA STEs were obtained from OA 
patients undergoing joint replacement surgery and are therefore in the end stage 
of the disease. Originally, it was thought that the condition of the synovium was 
correlated with OA severity and occurred gradually through the disease process 
(19, 20). However, Roemer et al. showed that baseline joint effusion and synovitis 
predicted the risk of cartilage loss after 30 months follow up (21). This indicates 
an important role for inflammation in an earlier stage of OA. Furthermore, Benito 
et al. demonstrated that early OA synovium has more features of inflammation 
(greater cell infiltration and overexpression of inflammatory mediators) than late OA 
synovium (8). In line with this, Ning et al. found a decreased expression of MMP-1, 
COX-2 and IL-1β expression in synovium depending upon the severity of OA (17). 
These previous observations are in agreement with our result that end stage OA 
STEs display an excretion profile that is rather similar to that of normal controls. 
The occurrence of inflammation resolving mechanisms in end stage OA STEs due 
to exposure to inflammatory triggers earlier in life might explain this observation. 
This is substantiated by its diminished responsiveness to a pro-inflammatory trigger. 
Potential molecular mechanism would be the down regulation of many receptors 
and a decreased secretion of resolving mediators to counter balance chronic 
inflammation. The fact that MMP activity seemed to be down regulated when co-
cultured with cartilage explants also contributes to this idea. Furthermore, end-stage 
OA STEs were not able to induce cartilage degeneration in a co-culture model which 
endorses the idea that synovium is not capable of initiating cartilage degradation. 
However, it does not rule out the possibility that it plays a role in progression and 
aggravation of the cartilage destruction process in OA, since we have not tested OA 
and normal STEs on OA-derived cartilage.
Beekhuizen et al. have demonstrated in a comparable in vitro co-culture model 
with matched OA cartilage and OA STEs an effect on GAG production, but not on GAG 
release (22). Due to our design, we were not able to determine GAG synthesis by, for 
example, the rate of sulphate incorporation. However, based on total GAG content 
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Remarkably, it seems that IL-1α is not involved in the activation of STEs leading 
to cartilage destruction, since no increase in GAG release was observed even though 
numerous soluble mediators were elevated. The effect of the IL-1α trigger on GAG 
release and MMP activity can be subscribed to its direct effect on chondrocytes 
without any contribution of IL-1a- stimulated STEs. However, other explanations 
could be that IL-1α overrules the effect of the secreted soluble mediators or not all 
human mediators excreted by STEs cross-react with bovine receptors.
Minor points of the study need to be addressed. As the excretion of soluble 
mediators is not corrected for the amount of cells, the absolute levels can be 
discussed. To reach feasible standardization in this experiment the results were based 
on multiple explants per donor with comparable weights. Furthermore, the presence 
of small pieces of other tissues as well as the injury response at collection cannot 
be fully excluded. At last, we cannot exclude that hypoxia in post mortem obtained 
normal STEs influenced the outcome of the study although hypoxia inducible factor-
driven VEGF levels were not different between normal and OA STEs (23, 24). Due to 
the fact that the procedures for OA and normal STEs were standardized we expect 
that the observed differences include comparable limitations.
In summary, we found the excretion profile of OA STEs to be comparable to 
that of normal donors. This is in contrast to what we had anticipated, namely more 
inflamed tissue with elevated secretion of pro-inflammatory mediators and MMPs. 
As such it is understandable that no contribution of the OA STEs was observed on 
cartilage destruction in the co-culture model. The responsiveness of the STEs to a 
pro-inflammatory trigger, however, indicates that there are differences in the state 
of the tissue between OA and normal donors. It suggests that end stage OA STEs are 
less sensitive to inflammatory stimulation which might be due to prolonged exposure 
to an inflammatory environment during disease progression. However, this does not 
rule out the involvement of STEs in an earlier phase of OA development. Further 
understanding of the pro-inflammatory and inflammation resolving mechanisms 
during disease progression in synovium may provide valuable targets for therapy in 
the future.
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Figure S1. Immunohistochemical staining for CD68+ cells in representative synovial tissue 
explants directly after acquiring. A. normal donor and B. OA donor. Magnification 20x
3
Metabolic profiling reveals differences in concentrations 
of oxylipins and fatty acids secreted by the infrapatellar fat 
pad of end-stage osteoarthritis and normal donors
L.M. Gierman1,2, S. Wopereis1, B. van El1, E.R. Verheij1, B.J.C. Werff-van der Vat.1, Y.M. 
Bastiaansen-Jenniskens3, G.J.V.M. van Osch3, M. Kloppenburg2, V. Stojanovic-Susulic4, T.W.J. 
Huizinga2, A.-M. Zuurmond1.
1TNO, Leiden, The Netherlands
2Leiden University Medical Center, Dept. of Rheumatology, Leiden, The Netherlands
3Erasmus MC. University Medical Center Rotterdam, Dept. of Orthopaedics and Dept. 
Otorhinolaryngology, Rotterdam, The Netherlands







































Objective: The infrapatellar fat pad (IPFP) in the knee joint is hypothesized to 
contribute to osteoarthritis (OA) development possibly by influencing inflammatory 
processes. Oxylipins are essential mediators in the inflammatory process. We aimed 
to identify the secretion of fatty acids and oxylipins derived thereof by the IPFP.
Methods: IPFP explants of 13 OA (joint replacement surgery) and 10 normal (post-
mortem) donors were cultured for 24 hours and supernatants were collected 
(FCM). Liquid chromatography-tandem mass spectrometry detected fatty acids and 
oxylipins in FCM samples. Univariate and multivariate (PLS-DA; Partial Least Squares 
Discriminant Analysis) analyses were performed followed by pathway analysis. To 
validate these outcomes a second set of OA FCM samples was measured (n=23).
Results: Twenty nine oxylipins and fatty acids could be detected in FCM. Univariate 
analysis showed no differences between normal and OA FCM, however PLS-DA 
revealed an oxylipin/fatty acid profile consisting of 14 mediators associated with 
OA (accuracy rate 72%). Most important contributors to the model were lipoxin 
A4 (decreased), thromboxane B2 (increased) and arachidonic acid (increased). The 
statistical model predicted 64% of the second set of OA FCM samples correctly. 
Pathway analysis indicated differences on individual mediators rather than complete 
pathways.
Conclusion: IPFP secretes multiple and different oxylipins and a subset thereof 
provides a distinctive profile for OA donors. The observed changes are likely 
regulated by the OA process rather than a consequence of basal metabolism changes 
as the increase in fatty acid levels was not necessarily associated with an increase in 
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Osteoarthritis (OA) is a complex joint disease with multiple risk factors leading to 
cartilage degradation (1). For a long time, the emphasis in OA research has primarily 
been on degeneration of articular cartilage. Nowadays it is considered a disease of 
the whole joint in which multiple joint tissues, such as synovial tissue, ligaments, 
muscles and bone, are involved or affected by the process (2, 3).
An important risk factor for OA is obesity, which was until recently related to 
increased mechanical load in obese individuals leading to cartilage degradation. 
However, recent findings, such as the association between obesity and OA in non-
weight bearing joints, suggest that there are other connections between obesity 
and OA (4, 5). Adipocytes and infiltrating immune cells in the adipose tissue actively 
secrete numerous cytokines and adipokines that in turn can influence metabolism 
and inflammatory responses in the body (6). These factors derived from adipose 
tissue may therefore contribute to the development of OA.
A special form of adipose tissue, named the infrapattelar fat pad (IPFP), is located 
intracapsularly and extrasynovially in the joint and is in close contact with synovial 
layers and articular cartilage. Its main role is to facilitate the distribution of synovial 
fluid and to absorb mechanical forces through the knee (7). Given the fact that 
adipose tissue is a highly active metabolic and endocrine organ, IPFP possibly has 
an important role in OA pathogenesis which only recently received attention. Its 
exact role in OA development still needs to be elucidated (8). Several cytokines are 
locally produced in the knee joint by the IPFP (9) and it has been found that IPFP 
derived from OA patients secretes higher levels of inflammatory mediators and has 
a different cell composition compared to subcutaneous fat (10). On the other hand, 
IPFP conditioned medium from end stage OA patients had anti-catabolic effects on 
cartilage explants in an in vitro culture experiment (11).
Other important signaling molecules implicated in the modulation of 
inflammatory responses are oxylipins. Oxylipins are formed from essential fatty 
acids via oxygenation and their biosynthesis is initiated via three major pathways, 
cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP). These lipid 
mediators are found in all tissues in the body and are involved in the control of many 
physiological processes (12, 13). The activity of the COX, LOX and CYP pathways and 





































for multiple inflammatory diseases such as rheumatoid arthritis, cardiovascular 
diseases and psoriasis (14). Pro-inflammatory oxylipins such as prostaglandin (PG)E2 
and leukotrienes (LT)B4 are produced by oxidation of omega (ω)-6 fatty acids such as 
arachidonic acid (AA) by the COX enzyme system. Oxidation of (ω)-3 fatty acids (such 
as EPA and DHA) give rise to the lesser inflammatory mediators as PGE3 following 
COX oxidation, and LTB5 following LOX activity (15).
The role of PGs in OA has been explored extensively (16, 17) and non-steroidal anti-
inflammatory drugs (NSAIDs) which reduce the production of PGE2 are commonly 
used in medical management of OA aiming to reduce pain. These drugs interfere, 
however, not only with PGE2 but also with other mediators that are generated by 
the same enzymatic pathways (18). The individual role of other mediators in OA has 
not received full attention, but may provide valuable targets for OA therapy (19, 20).
The main aim of this study was to investigate which fatty acids and oxygenated 
derivatives thereof (oxylipins) are secreted by the IPFP. Furthermore, we questioned 
whether an oxylipin and fatty acid secretion profile of the IPFP could distinguish 
between normal and OA donors using a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis approach (21-23). The results were used to 
construct biological networks, providing visualization of the interactions between 
identified markers. This integrated inspection might provide new insight in the role 








































Indomethacin, paraoxon and butylated hydroxytoluene (BHT) were from Sigma 
(Steinheim, Germany). Phenylmethylsulfonyl fluoride (PMSF) was from Fluka 
(Steinheim, Germany). 12-[(tricyclo[3.3.1.13,7]dec-1-ylamino) carbonyl]amino]-
dodecanoic acid (AUDA) was purchased from Cayman (Ann Arbor, MI, USA). Milli-Q 
water (MQ) (Milli-Q Advantage unit, Millipore, Amsterdam, The Netherlands) 
was used in all analyses. Ultra Liquid Chromatography (ULC)-grade acetonitrile 
(ACN), formic acid (FA) and trifluoro acetic acid (TFA) were obtained from Biosolve 
(Valkenswaard, The Netherlands). LC-MS grade methanol was from Riedel-de-Häen 
(Steinheim, Germany). Isopropanol and ethanol were from JT Baker (Deventer, The 
Netherlands). All analytical and internal standards were purchased from Cayman. For 
oxylipins, stock solutions were prepared in ethanol, aliquoted and stored at -80°C 
until analysis. Hydrophilic-lipophilic-balanced reversed-phase sorbent for acids, 
bases and neutrals (HLB) solid phase extraction (SPE) columns (Oasis, 60 mg, 3 mL) 
were from Waters (Etten-Leur, The Netherlands). 
Preparation of fat-conditioned medium of infrapatellar fat pad 
IPFP was obtained from 13 OA patients undergoing joint replacement surgery (OA-I) 
or from post-mortem material of 10 non-OA donors with macroscopically no signs 
and no clinical history of OA (normal). IPFP were obtained according to legal and 
ethical requirements approved by the institutional review board of the University 
of Pennsylvania including anonymous informed written consent from the donor or 
nearest relative (Articular Engineering, Northbrook, USA). Due to the anonymous 
collection, no information was available about these donors excluding age, sex and 
body mass index (BMI). Immediately after collection the inner parts of the fat pads, 
where no synovial tissue is present, were cut in small pieces and cultured in Dulbecco’s 
Modified Eagle medium (DMEM) + glutamax (Invitrogen, Paisley, UK), 1:100 Insulin-
transferrin-sodium selenite supplement (ITS) (Roche Diagnostics, Indianapolis, USA), 
1% penicillin and streptomycin (Pen Strep) (Biowitthaker Verviers, Belgium) and 0.1% 





































and incubated at 37°C. After 24 hours, the supernatant, i.e. fat-conditioned medium 
(FCM) was harvested, centrifuged at 300 g for 8 minutes and frozen at -80˚C in 
aliquots until analysis (Articular Engineering, Northbrook, USA). This incubation time 
was chosen arbitrarily since each mediator has its own optimum regarding release 
kinetics Furthermore, 23 FCM samples from end-stage OA patients, obtained and 
processed with a comparable protocol but at another laboratory, were included and 
are called OA-II in this manuscript (Erasmus MC, Rotterdam, the Netherlands, MEC-
2008-181). These OA-II FCM samples were used to validate the outcomes of the 
study. Demographic data of all included donors can be found in table 1.
Table 1. Demographic data of the normal and osteoarthritis (OA-I and OA-II) donors included.
Normal (n=10) OA-I (n=13) OA-II (n=23)
Age 62.1 (11.9) 62.5 (6.9) 64.5 (9.5)
Sex, M/F 6/4 8/5 7/16
BMI 24.4 (4.5) 32.0 (10.5) 29.9 (3.9)
Data are presented as mean (SD). Number of donors (n), Age in years, male (M), female (F), 
Body Mass Index (BMI).
Extraction of oxylipins and fatty acids from fat-conditioned medium
Samples were precipitated with methanol and 50 µl internal standards (Table S1) 
were added to 1 ml of the FCM samples and put on ice for 30 minutes. Negative 
controls, containing culture medium used in the processing of normal, OA-I and OA-
II samples which was not incubated with IPFP, were also included. Samples were 
subsequently centrifuged (5’ at 3000 x g and 4°C) and the supernatant was transferred 
to a glass tube. Just before loading on activated HLB columns, 4.75 mL MQ water 
containing 0.1% v/v FA was added to the methanol extract, diluting the extract to 
20% methanol. After loading, the columns were washed with 2 mL 20% methanol in 
MQ water containing 0.1% FA, and the columns were allowed to dry for 15 minutes. 
The SPE columns were eluted with 2 mL methanol and the samples were captured 
in tubes already containing 20 µL of 10% glycerol and 500 µM butylhydroxytolueen 
(BHT) in ethanol. The tubes were placed in a water bath at 40°C and the methanol 
was evaporated under a gentle stream of nitrogen, after which the samples were 
reconstituted in 100 µL ethanol containing internal standard (CUDA) (for monitoring 
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Liquid chromatography-mass spectroscopy (LC-MS)/MS analysis of oxylipins and 
fatty acids
All analyses were performed on an ultra-performance liquid chromatography (UPLC) 
coupled to a Xevo TQ-S mass spectrometer (Waters). Five µl extract was injected 
on an Acquity C18 BEH (ethylene bridged hybrid technology) UPLC column (2.1 x 
100 mm, 1.7 µm) and was separated using gradient elution with a stable flow of 
600 µl/min. The gradient started with 95% A (MQ water with 0.1% FA) and 5% B 
(ACN with 0.1% FA) followed by a linear increase to 70% A and 30% B which was 
achieved at 5.0 minutes. This was followed by a linear increase towards 50% B which 
was achieved at 11.25 minutes and maintained until 13.25 minutes. The system 
was subsequently switched to 100% B, which was achieved at 15.75 minutes and 
maintained until 16.75 minutes, after which the column was left to equilibrate at 5% 
B for approximately 3 minutes. The column was maintained at 50°C during analysis, 
and the samples were kept at 10°C. The MS was operating in selective reaction mode 
using electrospray ionization in negative ion mode, with a capillary voltage of 3.3 
kV, a source temperature of 150°C and a desolvation temperature of 600°C. Cone 
voltage and collision energy were optimized for each compound individually (consult 
table S1 for parent and product m/z values). Peak identification and quantification 
were performed using MassLynx software version 4.1. Calibration curves were 
run in duplicate from which one regression equation was generated after internal 
correction.
Statistical analysis and interpretation
Partial least square discriminant analyses (PLS-DA) (24) was used to identify oxylipins 
and fatty acids that differed between 13 OA-I and 10 normal FCM samples. Levels 
lower than the lowest level of the detection limit were replaced by 0.5 times the 
lowest level of detection. In PLS-DA, a y-variable containing class membership 
information is correlated to a data matrix (X-block). OA-I donors and normal donors 
were assigned to class 0 and class 1 respectively. The PLS-DA model was validated 
using a 10-fold double cross validation approach (25). The 23 OA-II samples were 
used to validate the statistical model for OA FCM samples. All multivariate data 





































Inc). Based on the outcomes of the PLS-DA, a pathway analysis was performed using 
Pathvisio in which the observations were visualized (www.pathvisio.org). A custom 
made pathway was created based on literature searches. Univariate analyses were 
performed with the parametric student t-test or non-parametric Mann-Witney test 
depending on their normal distribution as assessed with Levene’s test by using SPSS 
version 20.. Graphs were made by GraphPad Prism version 17.0.
Results
Lipid content of fat-conditioned medium
Metabolic profiling of oxylipins and fatty acids in FCM samples of 13 OA-I donors and 
10 normal donors was performed. This screening approach led to the identification 
of the lipid mediators presented in table 2. Out of 52 oxylipins and fatty acids that 
can be measured by this approach, 29 could be detected in the FCM samples. 
Additionally, 23 OA-II FCM samples, processed with the same protocol but at another 
laboratory, were measured and revealed to contain the same lipid mediators as the 
OA-I FCM samples, but at different concentrations (table S2).
Most fatty acids were detected (with exception of linoleic acid), i.e. arachidonic 
acid (AA) (ω-6), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (both 
ω-3), in the FCM samples of OA-I, OA-II and normal donors. No significant differences 
were detected between OA-I and normal donors when applying univariate statistical 
analysis, although AA showed a tendency of higher concentrations in OA-I FCM than 
in normal FCM (p=0.10) (Figure 1). DHA also showed a tendency towards higher 
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3Figure 1. Concentrations of essential fatty acids detected in fat-conditioned medium (FCM) 
samples of normal (n=10) and osteoarthritis ((OA)-I, n=13) donors. Concentrations of 
independently isolated OA FCM samples are also presented (OA-II, n=23). Line indicates the 
mean. Arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Using multivariate statistical analysis (PLS-DA), a set of 14 out of 29 quantified 
oxylipins and fatty acids was retained in a model which distinguished OA-I and from 
normal FCM samples with a median error rate of 28% after 10-fold double cross 
validation. The model provided a ranking (Table 3), in which lipoxin A4 was the 
most discriminative oxylipin between OA-I and normal FCM. The essential fatty acid 
AA was ranked on the third position and DHA was ranked as fifth. The individual 
concentrations of the 3 most discriminating oxylipins are illustrated in figure 2. Levels 
of lipoxin A4 were lower in OA-I than in normal FCM. Thromboxane B2 (TBXB2), 
an inactive metabolite of the biologically active TBXA2, was ranked on the second 
position and was higher in OA-I FCM than in normal FCM, whereas prostaglandin 
PGD3 (ranked fifth), a derivative from the ω-3 fatty acid EPA, was found to be lower 
in OA-I FCM. Furthermore, the precursor for resolvin D1, 17(S)HDoHE (derived from 
DHA), was higher in OA-I FCM. AA-derived PGF2α and D2 were higher in OA-I FCM, 
whereas PGB2 and F2β levels were lower. Finally, linoleic acid-derived 9-HODE and 
13-HODE were found to be lower in OA-I FCM. None of the resolvins, maresins and 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Validation of the osteoarthritis fat-conditioned medium samples
To assess whether the collected OA-I FCM samples were representative for OA, we 
included independently isolated FCM samples from 23 OA donors (OA-II) in the 
study. Regarding individual levels, the 14 lipid mediators obtained from the PLS-
DA model had different absolute mean values in the OA-I samples compared to the 
OA-II samples, although the majority was changed in the same direction compared 
to normal FCM (Figure 1 and 2, table S2). For TBXB2, 9(S)HODE and 17(S) HODE 
different patterns were seen in the OA FCM samples from different laboratories; with 
respect to normal FCM samples the TBXB2 levels were higher in OA-I while lower in 
OA-II samples. For 9(S)HODE and 17(S) HODE lower levels were found in OA-I than in 
normal FCM samples, in contrast to higher levels in OA-II samples. Additionally, the 
OA-II FCM samples were analyzed within the built statistical PLS-DA model of OA-I 
and normal samples. Eight out of 23 OA-II FCM samples were not classified as OA 
FCM sample by using this approach (error rate of 36%). 
Table 3. Ranking in partial least square discriminant analysis (PLS-DA) of 13 osteoarthritis 
(OA-I) and 10 normal donor derived fat-conditioned medium samples.
Rank Name Regression coefficient














The contribution of a variable in the PLS-DA model is expressed as its regression with a 
positive score indicating an increase and a negative score indicating a decrease in OA-I 
compared to control FCM samples. A greater absolute value means more contribution of this 
oxylipin to the measured differences between OA-I and normal FCM samples. Thromboxane 
B2 (TBXB2), arachidonic acid (AA), prostaglandin (PG), docosahexaenoic acid (DHA), 
hydroxy docosahexaenoic acid (HDoHE), dihydroxy eicosatrienoic acid (diHETrE), hydroxyl 
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3Figure 2. Concentrations of oxylipins which are high in the ranking in the contribution to 
the distinction between normal (n=10) and osteoarthritis ((OA)-I, n=13) donors derived fat- 
conditioned medium (FCM) samples after partial least square discriminant analysis (PLS-DA). 
Concentrations of independently isolated OA FCM samples are also presented (OA-II, n=23). 
Thromboxane B2 (TBXB2) and prostaglandine (PG)D3. Line indicates the mean.
Pathway analysis 
To visualize the results from the quantified fatty acids and oxylipins in the OA-I FCM 
samples, all data were imported and analyzed using Pathvisio (Figure 3). In this 
overview, the quantified fatty acids and oxylipins are shown together with their main 
enzymes (LOX, COX, and CYP). Herein it is shown that higher concentrations of the 
fatty acids not necessarily lead to higher concentrations of its downstream products. 
AA was found in higher concentrations in OA-I FCM than in normal FCM, but for its 
downstream products both higher and lower concentrations were found. None of the 
main enzymes (COX, LOX or CYP) seemed to be consistently up or down regulated, 
although all LOX-derived oxylipins in the PLS-DA model showed lower concentrations 
in OA-I patients. However, 3 out of 7 quantified LOX-derived oxylipins did not 
contribute to the discrimination of OA-I from normal donors. Oxylipins involved in 
the synthesis of lipoxin A4 (lipoxin A4 and 15-HETE) and downstream derivatives of 
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Discussion
The IPFP located in the knee joint is considered as a tissue that may contribute 
to local inflammatory and destructive processes in OA (8). Important signaling 
molecules implicated in the modulation of inflammatory responses are oxylipins 
(14). In this study, we provide a comprehensive approach to identify oxylipins and 
fatty acids secreted by the IPFP in the knee joint. Using an LC-MS/MS approach, 29 
out of the measurable 52 oxylipins and fatty acids could be detected in the FCM 
samples, indicating the presence of bioactive lipids in IPFP. None of these 29 lipid 
mediators differed significantly between OA-I and normal donors based on univariate 
statistics. By using multivariate analysis (PLS-DA), an oxylipin profile associated with 
OA-I was obtained with an accuracy rate of 72% after 10-fold double cross validation. 
The validation of the statistical model with independently isolated OA FCM samples 
(OA-II) revealed a comparable accuracy rate for OA samples (64%). These accuracy 
rates are acceptable given the relatively small included number of donors and 
the biological variety in these sample type. The measured changes visualized by 
pathway analysis demonstrated that the profile associated with OA FCM is likely to 
be specifically changed by the disease process rather than due to alterations in basal 
metabolism or generic enzymes as the increase of a fatty acid concentration was not 
necessarily associated with an increase in oxylipins derived from this fatty acid. 
In addition to the profiling of essential fatty acids and oxylipins secreted by 
IPFP, we wondered whether the profile of IPFP from OA would differ from normal 
donors. A difference may reveal more insight in the role of IPFP in the OA disease 
process. Based on multivariate analysis lipoxin A4, which is derived from AA, was 
the most discriminative oxylipin between OA-I and normal FCM with lower levels 
in OA donors. Also 15-HETE, an intermediate in lipoxin A4 synthesis, was found in 
decreased concentrations in OA-I compared to normal FCM. Lipoxin A4 is known to 
have a role in the resolution of inflammation, is produced by cartilage explants (26) 
and is present in OA and rheumatoid arthritis (RA) synovial fluid (27). Lipoxin A4 
inhibits interleukin (IL)-1β induced IL-6 and IL-8 release in fibroblast-like synoviocytes 
(FLS) and reduces matrix metalloproteinase (MMP)-3 release and increases tissue 





































12/15-lipoxygenase (12/15-LOX), a major enzyme involved in the generation of 
a subclass of oxylipins including lipoxin A4, in a mouse model for arthritis leads to 
uncontrolled inflammation and tissue damage (30). The lower concentrations of 
lipoxin A4 and 15-HETE in the OA-I compared to normal FCM samples contribute to 
the concept that lipoxin A4 may act as counter regulatory signal and has a potential 
to limit inflammation-induced tissue damage (31).
TBXB2 was ranked as the second oxylipin by PLS-DA that contributed to the 
distinction between OA-I and normal FCM samples. TBXB2 was elevated in OA-I 
compared to normal FCM samples. In FCM of the OA-II samples, however, this oxylipin 
was not different from normal FCM. This discrepancy may be explained by several 
reasons. Firstly, although the same protocol for the collection and processing of OA-I 
and OA-II FCM was applied, reliable detection of oxylipins may be disturbed by ex 
vivo degradation of lipid mediators due to rapid enzymatic conversion or chemical 
instability (32, 33). Therefore the generated absolute values and the differences 
between OA-I and OA-II samples should be interpreted with caution. Secondly, due to 
the anonymous collection of the FCM samples, the medical history of these patients 
is unknown. OA-I and OA-II FCM samples were collected in different countries and 
different protocols for the use of drugs prior to surgery may explain the discrepancy 
between OA-I and OA-II FCM samples. Especially, the use of pain killers such as 
NSAIDs or COX inhibitors, which interfere in pathways leading to the production 
of TBXB2, may explain these differences. It should as well be noted that the lack 
of information about the medical history of the donors also counts for the other 
observed differences between OA-I and normal donors and it cannot be excluded that 
this influences the detected levels. Most of the essential fatty acids were detected 
in the FCM samples. It has been postulated that the intake of dietary essential fatty 
acids can influence the development of OA (34). In a spontaneous OA guinea pig 
model an ω-3 rich diet was reported to improve histological and biochemical markers 
of OA (35). Unexpectedly, in our data DHA (ω-3) levels were higher in OA-I than 
normal derived FCM samples. EPA (ω-3) was not altered in OA-I compared to normal 
FCM samples. The higher secretion of the pro-inflammatory ω-6 fatty acid AA by OA 
IPFP was in line with our expectations. Notably, the different PGs derived from AA 
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samples. PGs exert diverse and complex modulatory roles during pathophysiologic 
conditions and are extensively investigated in relation to OA (16, 17, 20). PGE2, 
for example, is known to increase the productions of MMPs and pro-inflammatory 
soluble mediators which can lead to alterations in the cartilage, synovial membrane 
and bone. Remarkably, no differences between OA-I and normal FCM were observed 
for PGE2. Furthermore, PGD2 concentrations, which can augment the production 
of PGE2 (26), were not different between OA-I and normal FCM. The increase of 
the essential fatty acid AA but not necessarily their by-products supports the idea 
that the observed changes are specifically for the disease process and indicates the 
complexity of systemic equilibrium in these pathways. 
Although essential fatty acids were detected, some apparent by-products from 
pathways instigated by these fatty acids were not measured in the FCM samples, such 
as the leukotrienes which are suggested to increase bone resorption and to induce 
IL-1 synthesis (20, 36). Resolvins, which play an important role in the resolution 
of inflammation, were also not identified using this approach (37). The absence 
of these oxylipins might be due to the detection limit of our analysis and more 
sensitive methods may reveal their presence. Furthermore, as mentioned previously, 
concentrations may be influenced by ex vivo degradation of lipid mediators due to 
rapid enzymatic conversion or chemical instability (32). For all detected oxylipins and 
fatty acids, having identical MS/MS transitions, counts that they were distinguished 
by retention time after optimization of the chromatographic conditions using 
commercially available standards, however it cannot be fully excluded that other 
isomers may be present in biological materials that co-elute with those tested.
There are few references to such a broad lipid mediator approach performed in 
tissues and fluids in the knee joint. Attur et al. analyzed the excretion of a selected 
panel of oxylipins and their related fatty acids by OA and normal cartilage explants. The 
main outcomes were the increased spontaneous secretion of PGE2 and leukotriene 
B4 by OA compared to normal cartilage explants (26). A study with equine synovial 
fluid reported a radical change of the oxylipin profile after experimental induction of 
transient acute synovitis (e.g. PGE2, PGD2, PGF2a, leukotriene B4 and TBXB2) (38). 
Our data contribute to the theory that during the OA process the essential fatty acids 





































whether these changes in profiles contribute to the process of cartilage degeneration 
or are a consequence thereof. 
The extensive biological variance which was measured in the samples led to 
a multivariate statistical model with an error rate of 28%. This should be taken 
into account when interpreting the data. By the validation of the model with 
independently isolated OA FCM samples (OA-II) a comparable error rate for OA 
samples was obtained, which strengthens the observations measured in the OA-I 
FCM sample set. An expansion of the number of donors is needed to investigate 
whether the error rate can be reduced, thereby improving the reliability of the model 
and the validity that differences in oxylipin secretion are present between OA and 
normal IPFP. 
This study demonstrates that OA and normal IPFP generate multiple and 
different oxylipins. OA patients can be distinguished from normal donors based on 
the secretion of lipid mediators involved in the oxylipin pathways by IPFP. Pathway 
analysis underlined the complexity of equilibrated mechanisms in the OA process as 
an increase in a fatty acid not necessarily led to an increase in a by-product of the 
instigated pathway. These data may provide a basis for development of therapeutics 
in OA.
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Table S1. MS/MS parent and product ion m/z values
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Resolvin D2 375.1 175.0
Resolvin D1 375.1 140.8
LTE4 438.0 351.0
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Soluble mediators, e.g. cytokines, chemokines and growth factors, are acknowledged 
as key players in the pathophysiology of osteoarthritis (OA) (1, 2). However, a wide-
spectrum screening of such mediators in the joint environment is currently lacking. 
In this study, synovial fluid was collected from control donors and end-stage knee OA 
patients and analysed for 47 cytokines, chemokines and growth factors using several 
multiplex ELISAs. In addition, a principal component analysis (PCA) was performed to 
cluster the measured mediators. IL-6, IP-10, MDC, PDGF-AA and RANTES levels were 
found to be higher in OA compared to control synovial fluid (p<0.001). Leptin, IL-13, 
MIP-1β, sCD40L levels were higher and eotaxin and G-CSF levels were lower in OA 
synovial fluid than in control synovial fluid, albeit at borderline significance (p<0.05). 
Increased levels of inflammatory mediators and chemokines, such as MDC and IL-6, 
imply involvement of inflammatory processes in OA and might be associated with 
the influx of inflammatory cells in OA synovial tissue. Additionally, the PCA enabled 
identification of 6 different clusters, which explained 76% of the variance, and in this 
way could indicate different pathophysiological pathways in the joint. This dataset is 
valuable as a reference for future experiments to study pathophysiological pathways, 
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Brief report
A control group of knee synovial fluid samples (n=16) were collected from post 
mortem donors within 24 hours after death. Control donors had no history of OA, 
other joint pathology and possessed macroscopic healthy cartilage. OA synovial fluid 
samples (n=18) were collected during total knee arthroplasty. All OA patients were 
diagnosed according to the ACR criteria for OA (3). Exclusion criteria were rheumatoid 
arthritis (RA) or infection. Synovial fluid samples were centrifuged at 3000 rpm for 3 
minutes to spin down any cells or debris. The supernatant was stored at -80 °C until 
further analysis. The control synovial fluid samples were stored for 1 to 10 years and 
OA synovial fluid samples were stored for 1 to 3 years. None of the samples had 
ever been thawed before. Collection of the synovial fluid was done according to the 
Medical Ethical regulations of the University Medical Centre Utrecht and according 
to the guideline ‘good use of redundant tissue for clinical research’ constructed by 
the Dutch Federation of Medical Research Societies on collection of redundant tissue 
for research. As according to these guidelines, no information about the patients’ 
characteristics could be obtained. Gender and age information was available for 
limited donors. Control donors had an average age of 39.6 ± 9.3 and consisted of 55% 
female. OA donors had an average age of 69.9 ± 7.9 and consisted of 64 % female. 
Due to the limited availability these data could not be linked to any of the outcomes. 
Two hundred µl of each of the OA synovial fluid samples was pre-treated with 
20 µl of hyaluronidase (Sigma, St, Louis, MO, USA; 10 mg/ml) for 15 min at 37 °C. 
Samples were spun down in a X-column (Corning, Amsterdam, Netherlands; Costar 
8169). Finally, 150 µl of the synovial fluid sample was dissolved in 300 µl HPE-0.1375% 
Tween (Sanquin, Amsterdam, Netherlands). The pre-treated synovial fluid samples 
were used for all Multiplex ELISA assays mentioned below.
To determine a wide panel of soluble mediators the commercially available 
human inflammation 42-multiplex and the human adipokine 13-multiplex (Millipore, 
Bellirica, MA, USA) were used according to the manufacturer’s protocol. Additionally, 
12 different soluble mediators were measured with the Bio-Plex suspension system 
(Bio-Rad laboratories, Hercules CA, USA) as previously described (4). The levels of 





































measured in the same plate and in duplo. Levels below the lower limit of quantification 
(LLOQ) were indicated as the value of the lowest point on the calibration curve divided 
by 2. The measured mediators are listed in table 1. Data are expressed as median ± 
interquartile range (IqR) as the data had a non-Gaussian distribution. IBM SPSS 20.0 
software (IBM SPSS Inc. Chicago, IL, USA) was used for the statistical analysis. 
For this study, a descriptive statistics approach was used for the interpretation of 
the data due to the limited sample size. A Mann Whitney-U test was used to assess 
differences between control and OA synovial fluid samples due to the predominantly 
non-Gaussian distribution of the data. As a descriptive statistic approach was used, 
values with a p-value less than 0.001 were considered significant. P values between 
0.05 and 0.001 were considered borderline significant. No post-hoc correction for 
multiple testing was performed on the data, due to the descriptive approach.
PCA was performed to enable identification of clusters (i.e. components) of 
interrelated mediators within the complete dataset. Mediator levels were mean-
centered to remove dependence on magnitude of levels. Control and OA patient data 
were combined in one single PCA analysis. Separate analysis of patients and controls 
was judged impossible due to the limited number of subjects. Only mediators with 
communalities > 0.3 were included. Loading factors were maximized using Direct 
oblimin rotation with Kaiser Normalisation. The optimum number of clusters was 
then decided based on the scree-plot and eigenvalues (> 1.0). Mediators were 
categorized per cluster when their loading scores were > 0.5. A Crohnbach’s a was 
performed on each cluster to determine internal consistency. 
This is one of the first studies in which such a comprehensive profile of soluble 
mediators was measured in synovial fluid from (end-stage) OA patients and control 
donors. With regard to previous studies, the pattern of the mediator levels was found 
to be compatible for OA donors. However, in these studies a small panel of mediators 
was measured and the inclusion of control donors was lacking (e.g. (5)). Table 1 
provides an overview of the measured levels of each mediator (median ± IqR). The 
majority of the soluble mediators could be detected in the synovial fluid samples 
of both control and OA donors. Of the 47 measured mediators, 5 mediators were 
present at significantly different levels in OA compared to control synovial fluid. The 
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the pro-inflammatory cytokine IL-6 were significantly higher in OA than in control 
synovial fluid (p < 0.001). In addition, levels of the adipokine leptin, the chemokine 
MIP-1β, and the pro-inflammatory cytokine sCD40L were higher and levels of the 
chemokine eotaxin and the growth factor G-CSF were lower in OA than in control 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Pattern matrix after Oblimin rotation with Kaiser Normalisation as obtained from PCA 
in the spectrum of synovial fluid mediators. 
Action Mediator Cluster



















Growth factor PDGF-AB/BB -0.935
Growth factor PDGF-AA -0.914
Chemokine IP-10 -0.705
Growth factor sCD40L -0.683
Pro-inflammatory IFNa -0.589
T-cell factor Flt-3 ligand -0.827
Growth factor HGF -0.795
T-cell factor IL-15 -0.703
T-cell factor sIL-2ra -0.565
Adipokine IL-6 0.922
Adipokine Resistin 0.678
Eigenvalues 10.5 5.8 3.8 2.2 2.1 2.1
Variances explained (%) 30% 17% 11% 6% 6% 6%
Cronbach’s alphas 0.835 0.059 0.114 0.615 0.070 0.115
Control and osteoarthritic samples are combined. Only loading factors > 0.5 are displayed.
The PCA was performed to gain insight into the associations between individual 
mediators that were assessed. The PCA showed communalities > 0.3, which as such, 
were included in the analysis. PCA enabled identification of 6 clusters of interrelated 
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important pathophysiological pathways in the joint. In the pattern matrix, the 
mediators IFNγ, OSM, IL-7, IL-1β, IL-8 and TGFa were clustered in the first cluster, 
and together explained 30.2 % of the total variance with an eigenvalue of 10.5. 
Cluster 2 included IL-3, MIP-1a, EGF, leptin and IL-12, (variance explained 16.8%, 
eigenvalue 5.9). Cluster 3, contained MCP-1, IL-10, eotaxin and G-CSF (variance 
explained 10.8%; eigenvalue 3.8). Cluster 4 contained RANTES, PDGF-AB/BB, PDGF-
AA, sCD40L, IP-10, IFNa (variance explained 6.4%, eigenvalue 2.2). Cluster 5 included 
Flt-3 ligand, HGF, IL-15 and sIL-2ra (variance explained 6.1%, eigenvalue 2.1). Cluster 
6 included the adipokines IL-6 and resistin (variance explained 6.0%, eigenvalue 
2.1). In total, these 6 clusters explained more than 76% of the variance. The first 
two clusters mainly contained pro-inflammatory mediators and cluster 3 included 
predominantly chemokines. Cluster 4 contained predominantly growth factors and 
cluster 5 factors associated with T-cell proliferation and maturation. Finally, cluster 
6 contained only adipokines. Mediators in all these 6 clusters are known to be part 
of important processes in the joint homeostasis. However, distinguishing between 
potential clusters was difficult, since these mediators are involved in adjacent and 
interrelated pathways. 
Cytokines, chemokines, adipokines and growth factors play a major role in 
inflammatory diseases, such as OA, and are currently intensively studied. The 
adipokines are associated with obesity, which is in itself associated with low-grade 
systemic inflammation, one of the risk factors for the development and progression of 
OA (2, 6, 7). The different levels of IL-6, leptin and adiponectin between control and OA 
synovial fluid might indicate a role for certain adipokines in OA processes, which is in 
line with literature (7). However, these data were not corrected for BMI, which might 
influence the outcomes. Another group of mediators consisted of chemokines. The 
measured chemokines such as the related Chemokines-Chemokines (CC) mediators 
RANTES, MDC, MIP-1a and MIP-1b were higher in OA than in control synovial fluid. 
This group of chemokines share the same receptor complexes, e.g. CCR1, CCR2 
and CCR5 (8) and their major function is to attract inflammatory cells, e.g. T-cells, 
macrophages and other inflammatory cells to sites of inflammation. Chemokines, 
such as RANTES, are also capable of activating (inflammatory) cells in the production 





































production of IL-6 by synovial fibroblasts and enhances the inflammatory response in 
OA through the different CCR receptor in synovial tissue (9). Moreover, CCR receptors 
are present in chondrocytes and treatment of cartilage explants with RANTES was 
demonstrated to increase release of proteoglycans (10). The combination of multiple 
CC-chemokines in combination with IL-6 and leptin in the synovial fluid was not 
demonstrated earlier. Blocking these CC-chemokines or their receptors in OA might 
reduce IL-6 and leptin production and, consequently, the infiltration of inflammatory 
cells and the production of catabolic factors in the joint. Future research is necessary 
to elucidate this. 
In none of the synovial fluid samples GM-CSF, IL-12(p70), IL-13, IL-17, IL-2, IL-
4, IL-5, IL-7, IL-9, TNFb, VEGF and NGF and TNFa, could be detected. IL-1 was only 
detected at very low levels. TNFα and IL-1 are pro-inflammatory cytokines, which 
are associated with cartilage degeneration, synovial inflammation and bone changes 
(11). Although in some in vivo animal models of OA, blocking IL-1 or TNFa gave 
promising results, this could not be validated in clinical studies (12). Our results 
likewise do not support a prominent role for IL-1 and TNFα in end-stage OA patients. 
Nonetheless, this does not exclude a role for IL-1 and TNFα in for example early OA, 
as OA has a heterogeneous character with multiple phenotypes. 
For the interpretation of the data it should be mentioned that our results are 
based on a small sample size, due to donor availability, which were not paired on age, 
BMI and sex. Moreover, it should be taken into account that ex-vivo modifications 
cannot be excluded for the control donors as samples were taken after death. Also 
due to the small sample size, no further statistics were performed on the PCA to 
study differences between the clusters for OA and control synovial fluid samples. 
Therefore this pilot dataset should be regarded as a reference and more extensive 
profiling studies are necessary to confirm these data.
In summary, this is the first study measuring a wide panel of mediators in the 
synovial fluid of both control and end-stage OA donors. Increased levels of mediators 
such as MDC, IL-6 and RANTES once more confirm involvement of inflammatory 
processes and might be associated with the influx of inflammatory cells in OA synovial 
tissue. In addition, the PCA indicated 6 clusters, which reflect different processes 
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Nonetheless, this pilot dataset provides a valuable reference for future experiments 
to study pathophysiological pathways, and to be useful in more extensive profiling 
studies for OA. 
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Objective: Obesity is associated with systemic inflammation and is a risk factor for 
osteoarthritis (OA) development. We undertook this study to test the hypothesis that 
metabolic stress–induced inflammation, and not mechanical overload, is responsible 
for the development of high-fat diet–induced OA in mice.
Methods: Human C-reactive protein (CRP)–transgenic mice received a high-fat diet 
without or with 0.005% (weight/weight) rosuvastatin or 0.018% (w/w) rosiglitazone, 
2 different drugs with antiinflammatory properties. Mice fed chow were included as 
controls. After 42 weeks, mice were killed and histologic OA grading of the knees was 
performed. To monitor the overall inflammation state, systemic human CRP levels 
were determined.
Results: Male mice on a high-fat diet had significantly higher OA grades than mice 
on chow and showed no correlation between OA severity and body weight. In 
male mice, high-fat diet–induced OA was significantly inhibited by rosuvastatin or 
rosiglitazone to OA grades observed in control mice. Both treatments resulted in 
reduced human CRP levels. Furthermore, a positive correlation was found between 
the relative individual induction of human CRP evoked by a high-fat diet on day 3 and 
OA grade at end point.
Conclusion: High-fat diet–induced OA in mice is due to low-grade inflammation 
and not to mechanical overload, since no relationship between body weight and 
OA grade was observed. Moreover, the OA process was inhibited to a great extent 
by treatment with 2 drugs with antiinflammatory properties. The inflammatory 
response to a metabolic high-fat challenge may predict individual susceptibility to 
developing OA later in life. The use of statins or peroxisome proliferator–activated 
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Osteoarthritis (OA) is a chronic degenerative joint disease with large consequences 
for the quality of life of patients. It is now generally accepted that OA is not only a 
disease of articular cartilage, but in fact involves the entire joint, including Hoffa’s fat 
pad, synovium, subchondral bone, menisci, and ligaments. Insight into the different 
underlying processes leading to the clinical and pathologic outcomes of OA is crucial 
in the search for new therapies (1, 2). 
Obesity is a risk factor for the development of OA and is classically seen as a 
biomechanical factor, suggesting that the increase of loading forces causes cartilage 
damage. However, from the association between obesity and OA of non–load 
bearing joints it is hypothesized that systemic factors induced by obesity contribute 
considerably to the initiation and progression of OA (3). Obesity is associated with a 
mild chronic inflammation, and adipokines secreted by adipocytes and macrophages 
within adipose tissue are suggested to be a metabolic link between obesity and 
OA (4, 5). However, the relative contribution of these processes in the onset and 
progression of OA remains unclear.
The association between obesity and the development of OA has been studied in 
several animal models. Previously, Sokoloff et al showed that high-fat diet–induced 
obesity caused OA in 2 different mouse strains and in a rat strain. In addition, STR/Ort 
mice, which are vulnerable to spontaneous obesity, developed OA in a short period 
of time (6). The incidence of knee OA was found to be twice as high in C57BL/6 mice 
on a high-fat diet than in the control group fed with a chow diet. Changes associated 
with the human metabolic syndrome such as abdominal obesity, hyperglycemia, 
hyperinsulinemia, and hypertension are also present in these animals (7, 8). Although 
some of these diet-induced OA mouse model studies support a role of mechanical 
factors in the progression of OA, a correlation between body weight and OA is lacking. 
The fact that adipose tissue of C57BL/6 mice can become inflamed under conditions 
of metabolic stress (e.g., high-fat diet feeding) and secrete a broad spectrum of 
inflammatory mediators (9) suggests that high-fat diet–fed C57BL/6 mice constitute 
a suitable model to study the role of (metabolic stress–induced) inflammation in the 
development of OA.
The human C-reactive protein (CRP)–transgenic mouse model enables us to study 





































marker for systemic inflammation in humans, but not in wild-type mice, where its 
serum levels never rise above 2–3 mg/liter (10). CRP is produced by hepatocytes and 
adipocytes and is regulated by proinflammatory cytokines. Human CRP–transgenic 
mice carry the entire human CRP gene, including the coding region and 17 kb of 
the 5’-flanking promoter region, and the expression of human CRP in these mice 
resembles its regulation in humans. Unlike its wild-type mouse counterpart, human 
CRP behaves as a major acute-phase reactant when introduced into the mouse 
genome (11). Obese individuals are found to have higher CRP levels, indicating a low-
grade inflammation state (12, 13). Obese human CRP–transgenic mice on a C57BL/6 
background are therefore an interesting model for analyzing the role of inflammation 
in the development of OA. Modulation of this metabolic stress–induced inflammation 
provides a tool to gain more insight into the relevant contribution of this process in 
OA.
Statins and peroxisome proliferator–activated receptor γ (PPARγ) agonists have 
been shown to have important pleiotropic antiinflammatory effects in a number 
of studies and are therefore interesting interventions for studying the role of 
inflammation in OA (14-16). Statins are inhibitors of the rate-determining enzyme in 
the biosynthesis of cholesterol and are considered the most effective drugs to reduce 
serum cholesterol levels (17). PPARγ receptors are nuclear hormone receptors and 
are expressed at high levels in adipose tissue (18). PPARγ agonists bind to and 
activate these receptors and are used for the treatment of type 2 diabetes mellitus. 
In recent studies, PPARγ ligands were shown to have a wide spectrum of actions in 
the treatment of metabolic disorders (19, 20).
Statin or PPARγ agonist therapy for OA has been suggested in the literature (19, 
21, 22); however, in vivo data demonstrating the use of these drugs are scarce. 
Treatment with statins or PPARγ agonists in animals with experimentally induced OA 
resulted in reduced cartilage degradation, probably due to decreased inflammatory 
cell infiltration and matrix-degrading enzyme expression (23-25). However, their 
effect in high-fat diet–induced OA has not been investigated.
In this study, we hypothesize that high-fat diet–induced OA in mice is not due 
to mechanical overload, but is the consequence of metabolic stress–induced 
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overall inflammation state during the high-fat diet. Interventions with statins and 
PPARγ agonists were applied to suppress metabolic stress–induced inflammation to 
demonstrate that this process is involved in the pathogenesis of OA under conditions 
of obesity and the metabolic syndrome.
Methods
Animals
Human CRP–transgenic mice (11, 26) on a C57BL/6 background were characterized 
by polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) for 
human CRP expression. Mice were housed in groups under standard conditions on 
a 12-hour light/dark cycle and had free access to water and food. Experiments were 
approved by the Institutional Animal Care and Use Committee of TNO and were in 
compliance with European Community specifications regarding the use of laboratory 
animals.
Diets
Human CRP–transgenic 12-week-old male and female mice were fed standard lab 
chow (V1534; Ssniff Spezialdiäten) (time 0). After 4 weeks (time 4) the diets were 
changed, and mice were randomly distributed in 3 groups consisting of 9 male and 
9 female mice. Group 1 consisted of control mice that remained on a standard chow 
diet. Mice in group 2 were switched to a high-fat diet (D12451, 23.1% fat; Ssniff 
Spezialdiäten), and mice in group 3 were fed a high-fat diet containing 0.018% 
(weight/weight) rosiglitazone (GlaxoSmithKline). Besides these 3 groups, another 
group (group 4) was added that received chow supplemented with 0.01% (w/w) 
rosuvastatin (AstraZeneca) (time 0), which was continued in a high-fat diet after 
4 weeks but at a lower dosage of 0.005% (w/w) because of increased absorption 
of rosuvastatin on high-fat diets. Rosuvastatin and rosiglitazone doses were based 
on their antiinflammatory effects observed in previous studies (27, 28). Chow-fed 
control mice (group 1), untreated mice on a high-fat diet (group 2), and treated 
mice on a high-fat diet (groups 3 and 4) remained on their respective diets until the 






































At end point (time 42), knee joints of the hind limbs were fixed in a 10% neutral 
buffered formalin solution (Sigma-Aldrich), decalcified in Kristensen’s solution 
(29), dehydrated, and embedded in paraffin for histologic analysis. Serial coronal 
5 μm sections were collected throughout the patella, medial and lateral joint. 
Sections were stained with hematoxylin, fast green, and Safranin O as well as with 
hematoxylin–phloxine–saffron. Sections were randomly scored in a blinded manner 
at 3 locations in the joint: the femorotibial joint at the lateral side, the femorotibial 
joint at the medial side, and the patellofemoral joint. The scoring system included 
changes in articular cartilage structure, proteoglycan depletion, and chondrocyte 
morphology. The whole joint was scored following the international guidelines of 
the Osteoarthritis Research Society International (OARSI) histologic grading system 
(30). Briefly, this scoring system is based on a combined assessment of severity (from 
grade 0 = surface and cartilage intact to grade 6 = deformation) and extent (from 
stage 0 = no OA activity to stage 4 = >50% OA activity) of OA in the articular cartilage 
(grade by stage).
Human CRP levels
To monitor metabolic stress–induced inflammatory changes and the antiinflammatory 
effects of rosuvastatin and rosiglitazone using human CRP levels, after 4 hours of 
food deprivation blood was obtained by tail incisions and collected in EDTA tubes 
for plasma preparation (Sarstedt) at times 0, 2, 4, 4.5, 5, 11, and 34 weeks. Tubes 
were centrifuged for 10 minutes at 6,000 revolutions per minute, and plasma was 
immediately stored at −80°C until analysis. Human CRP was quantified in the plasma 
samples by established ELISA (R&D Systems).
To characterize the inflammatory responsiveness of the mice and to verify the 
antiinflammatory effects of rosuvastatin and rosiglitazone, all groups on high-fat 
diets were injected intraperitoneally (IP) with 100 μl interleukin-1β (IL-1β; PeproTech) 
at a mild dose (∼200 ng) 2 weeks before (time 2) and 8 weeks after (time 12) diet 
switch. The concentration used in this study is negligible compared with that used in 
previous models in which IL-1 was injected intraarticularly into the mouse knee joint 
(31). Plasma samples were collected prior to and 18 hours after this challenge and 
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Cytokine measurements
At end point, blood was collected by heart puncture and centrifuged for 5 minutes 
at 10,000 rpm. Serum samples were immediately stored at −80°C. Levels of the 
cytokines IL-6, leptin, resistin, and tumor necrosis factor α (TNFα) were measured 
in the serum samples using a multiplex bead immunoassay (Millipore) for mice with 
the Luminex 100 instrument. All samples were analyzed as recommended by the 
manufacturer.
Insulin levels
To determine the effects of high-fat diet and treatment on insulin, levels were 
measured at times 5 and 11 in plasma samples using an ELISA (Mercodia).
Statistical analysis
Statistical analysis was performed using the nonparametric Kruskal-Wallis and Mann-
Whitney U tests. Pearson’s correlation coefficient was used to assess the relationship 
between OA grade and human CRP levels. P values less than 0.05 were considered 
significant. Unless stated otherwise, data are shown as the mean ± SD.
Results
Body weight and body fat
Male mice in all the high-fat diet groups (treated and untreated) had significantly 
higher mean ± SEM body weights at the end of the study compared to the chow-fed 
control group. Male mice treated with rosiglitazone had the highest mean ± SEM 
body weight due to an increased fat accumulation, and this weight was significantly 
higher than that in the untreated high-fat diet group (untreated high-fat diet group 
41.4 ± 1.6 grams, P < 0.01 versus chow-fed control group [35.1 ± 0.6 grams]; high-
fat diet with rosuvastatin group 46.1 ± 2.3 grams, P < 0.01 versus chow-fed control 
group; high-fat diet with rosiglitazone group 57.7 ± 3.9 grams, P < 0.001 versus chow-
fed control group and untreated high-fat diet group) (Figure 1A). Female mice on 
a high-fat diet also had increased body weights compared to the chow-fed control 





































fed control group [28.0 ± 1.0 grams]; high-fat diet with rosuvastatin group 37.7 ± 
2.0 grams, P < 0.001 versus chow-fed control group; high-fat diet with rosiglitazone 
group 41.6 ± 2.5 grams, P < 0.001 versus chow-fed control group) (Figure 1B).
Figure 1. Body weights in each group during the study of male (A) and female (B) human 
C-reactive protein–transgenic mice. Male mice had a higher average body weight compared 
to female mice. Values are the mean ± SEM. ∗∗ = p < 0.01; ∗∗∗ = p < 0.001 versus chow-fed 
control group. ### = p < 0.001 versus untreated high-fat diet (HFD) group.
Gonadal, visceral, and subcutaneous fat content of each mouse was summed together 
to obtain the total fat content and was subsequently expressed as a percentage of the 
body mass of each mouse at end point. Control female mice on chow had a relatively 
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3.4 ± 1.0%; P < 0.05). High-fat diet groups (treated and untreated) had significantly 
higher percentages of fat than did the chow-fed control group, both for male mice 
(untreated high-fat diet group 7.1 ± 1.4%, high-fat diet with rosuvastatin group 8.5 
± 3.1%, high-fat diet with rosiglitazone group 7.7 ± 1.4%; all P < 0.001 versus chow-
fed control group) and for female mice (untreated high-fat diet group 9.2 ± 3.0%, 
P < 0.001 versus chow-fed control group; high-fat diet with rosuvastatin group 12.4 ± 
2.6%, P < 0.001 versus chow-fed control group; high-fat diet with rosiglitazone group 
6.5 ± 1.5%, P < 0.05 versus chow-fed control group).
Effects of high-fat diet and antiinflammatory interventions on OA development
On macroscopic evaluation, male mice from the untreated high-fat diet group had 
red, swollen knee joints with malformed morphology, which was not present in male 
mice from the chow-fed control group. High-fat diet groups treated with rosuvastatin 
or rosiglitazone did not have such macroscopic alterations. No macroscopic abnormal 
joint morphologies were observed in any female mice in the chow-fed control group 
or in the untreated or treated high-fat diet groups.
To determine microscopic differences, hematoxylin–, fast green–, and Safranin 
O–stained slides as well as hematoxylin–phloxine–saffron–stained slides of all knee 
joints were scored on different components. All joints had at least some minor OA 
changes such as slight fibrillation, hypocellularity, and Safranin O loss (Figure 2). 
Using the OARSI grading system, male and female mice on chow had comparable 
low mean ± SD OA grades (4.4 ± 2.9 versus 2.9 ± 1.6, respectively; P = 0.3). Male mice 
receiving a high-fat diet instead of chow had significantly higher OA grades at end 
point. Severely affected mice had cartilage loss, bone deformation, and osteophyte 
formation (Figures 2C and D), while the joints of treated mice were comparable to 





































Figure 2. Representative Safranin O–, fast green–, and hematoxylin-stained coronal sections of 
the whole knee joint (A, C, E, and G) with a detailed picture of the medial femoral condyle and 
tibial plateau (B, D, F, and H) of human C-reactive protein–transgenic male mice in the chow-
fed control group (A and B), the untreated high-fat diet group (C and D), the high-fat diet with 
rosuvastatin group (E and F), and the high-fat diet with rosiglitazone group (G and H). Bars = 2 




































Role of inflammation in osteoarthritis
5
Modulation of metabolic stress–induced inflammation with rosuvastatin or 
rosiglitazone in male mice on high-fat diets resulted in completely reduced mean 
± SD OA grades (high-fat diet with rosuvastatin group 3.8 ± 1.3, P < 0.01 versus 
untreated high-fat diet group [10.1 ± 6.0]; high-fat diet with rosiglitazone group 4.4 
± 0.9, P < 0.05 versus untreated high-fat diet group) (Figure 3A). Remarkably, OA 
grades observed in the treatment groups were comparable to those in mice fed with 
chow. In contrast to male mice, untreated female mice receiving high-fat diets hardly 
developed OA, as judged from their OA grades, which were comparable to those 
of their chow-fed controls. Treatment with rosuvastatin and rosiglitazone in female 
mice yielded mean ± SD OA grades similar to those of the untreated high-fat diet 
group (untreated high-fat diet group 4.7 ± 3.7, high-fat diet with rosuvastatin group 
5.4 ± 2.7, high-fat diet with rosiglitazone group 2.0 ± 0.0) (Figure 3B). Analysis of the 
individual components (lateral and medial femorotibial joint, patellofemoral joint) 
for cartilage structure, chondrocyte morphology, and Safranin O staining summed 
together showed results similar to those of the OA score (OARSI grade by stage) for 
the whole joint.
To investigate a possible influence of mechanical forces, body weight and body 
fat were correlated with OA development. OA grades of male mice in the untreated 
high-fat diet group were not significantly correlated with body weight or body fat, 
ruling out mechanical stress and fat mass as important factors for OA in this model.
Figure 3. Histologic osteoarthritis (OA) grade of the knee joints of male (A) and female (B) 
human C-reactive protein–transgenic mice. Rosuvastatin and rosiglitazone decreased the OA 
grade in male mice significantly. There were no significant differences in female mice (p = 0.13 
by Kruskal-Wallis test). Values are the mean ± SD. ∗ = p < 0.05; ∗∗ = p < 0.01 versus untreated 





































Effects of high-fat diet and antiinflammatory interventions on human CRP, cytokine, 
and insulin levels
Human CRP levels were measured during the experiment to monitor the overall 
inflammation state during high-fat diets as well as the effects of intervention with 
rosuvastatin and rosiglitazone. Before diet switch, all male mice on chow had similar 
baseline human CRP levels. In all cases, the switch to high-fat diets resulted in an 
increase in human CRP levels. Although not significant at every analyzed time point, 
rosiglitazone- and rosuvastatin-treated mice had lower human CRP levels than 
those in untreated mice on a high-fat diet. At a later phase of the study (time 34), 
human CRP levels decreased back to baseline levels (Figure 4). All female mice had 
an ∼1,000-fold lower level of human CRP compared to male mice, and there was no 
effect of rosuvastatin or rosiglitazone (data not shown).
Figure 4. Human C-reactive protein (CRP) levels in male mouse plasma at several time points 
during the study. Values are the mean ± SD. Dashed lines represent groups before diet 
switch. Overall, rosiglitazone- and rosuvastatin-treated mice showed lower human CRP levels 
compared to untreated mice on a high-fat diet (HFD) after diet switch (vertical and horizontal 
dotted lines), although the difference was not significant at every time point. At times 2 and 
4 weeks, untreated mice in the chow-fed control group showed significantly higher human 
CRP levels compared to rosuvastatin-treated mice in the chow-fed control group. ∗∗∗ = p < 
0.001 versus rosuvastatin-treated mice in the chow-fed control group. At time 4.5 weeks, 
untreated mice on a high-fat diet showed significantly higher human CRP levels compared to 
rosuvastatin-treated mice on a high-fat diet. ∗ = p < 0.05 versus rosuvastatin-treated mice on a 
high-fat diet. At times 11 and 34 weeks, untreated mice on a high-fat diet showed significantly 
higher human CRP levels compared to rosiglitazone-treated mice. ## = p < 0.01; ### = p < 
0.001 versus rosiglitazone-treated mice. Human CRP levels in female mice were 1,000-fold 
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To assess obesity-related cytokines, a multiplex assay was performed on serum 
samples collected from male and female mice at end point. Levels of IL-6 and 
TNFα were below the limit of detection. Leptin and resistin levels were high and 
increased in high-fat diet groups (treated and untreated) compared to those in the 
respective chow-fed control groups (Figures 5A and B). Treatment with rosuvastatin 
or rosiglitazone did not significantly alter leptin or resistin levels compared to those 
in the untreated high-fat diet group. No apparent differences between male and 
female mice were observed for leptin and resistin levels. No significant correlations 
were found in any of the groups between leptin or resistin levels and OA grade at end 
point (data not shown).
Insulin levels were measured to detect the effects of high-fat diet and intervention 
with rosuvastatin or rosiglitazone on the development of insulin resistance in this 
mouse model. At time 5, 1 week after diet switch, mean ± SD insulin levels were 
significantly suppressed in rosiglitazone-treated male mice on a high-fat diet 
compared to those in untreated male mice on a high-fat diet (0.5 ± 0.2 μg/liter versus 
0.9 ± 0.5 μg/liter; P < 0.004). Treatment with rosuvastatin did not alter insulin levels 
(1.1 ± 0.6 μg/liter) compared to those in untreated mice on a high-fat diet. The same 
effects were still observed at time 11. Insulin levels in female mice were very low, and 
there were no significant differences between groups.
Figure 5. Serum cytokine concentrations of leptin (A) or resistin (B) at end point (time 42 
weeks) in chow-fed control mice, untreated mice on a high-fat diet (HFD), and mice on a high-
fat diet treated with rosuvastatin or rosiglitazone. Values are the mean ± SD. ∗∗∗ = P < 0.001 






































Initial response to metabolic high-fat stress correlates with OA at end point
The initial response to metabolic high-fat stress (during the first days of high-fat diet 
feeding) was determined by calculating the difference in plasma levels of human CRP 
before and after diet switch. We correlated individual changes in human CRP level 
with individual OA grades at end point (Table 1). The initial response to high-fat diet 
feeding (3 days on a high-fat diet; time 4.5 weeks) was significantly correlated with 
OA. This relationship was lost for human CRP levels determined at later time points, 
indicating that the inflammatory response evoked by a metabolic stressor predicts 
susceptibility to developing OA at the level of an individual subject. This notion was 
further substantiated by demonstrating that no correlation was found between OA 
and change in human CRP level when human CRP was evoked by a nonmetabolic 
inducer of inflammation (200 ng IL-1 injected IP) (data not shown).
Table 1. Correlation between relative individual induction of huCRP levels (compared to t=4 
weeks; diet switch) and individual end point OA grades. 
Δ huCRP level µg/ml weeks (t) OA grade
Mouse        t# 4.5 5 11 34 42
1 8.8 3.9 17.6 1.2 9
2 16.3 16.2 13.5 4.1 15
3 37.5 5.5 4.9 1.1 20
4 -1.2 4.3 1.4 -0.8 4
5 9.0 11.2 3.7 -1.1 18
6 4.1 10.1 1.1 0.3 6
7 -0.6 0.8 3.3 -0.4 6
8 -0.6 2.5 2.1 0.6 9
9 -0.1 0.9 2.5 0.6 4
Mean ± SEM 8.1 ± 4.2 6.1 ± 1.8 5.6 ± 2.0 0.6 ± 0.5 10.1 ± 2.0
correlation
Δ CRP-OA grade 0.83** 0.54 0.28 0.30
Values are tested with a 2-tailed Pearson correlation test. Only correlation directly after diet 
switch (t=4.5) was statistically significant **p < 0.01
Discussion
Obesity is associated with low-grade systemic inflammation and is a risk factor for 
OA development. Whether this mild chronic inflammation or other factors such 
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 This study provides evidence for a role of metabolic stress–induced systemic 
inflammation in the development of OA. High-fat diet feeding in human CRP–
transgenic mice led to severe OA development compared to chow-fed control mice. 
We found no correlation between OA and individual body weight or fat mass, which 
excludes mechanical stress as a major trigger of OA in the present experimental 
setting. Instead, we demonstrated that antiinflammatory intervention with either 
rosuvastatin or rosiglitazone suppressed OA development to a great extent. This 
strongly suggests that metabolic stress–induced inflammation plays a major role in 
the onset and progression of high-fat diet–induced OA in mice.
In the clinic, statins are used as cholesterol-lowering drugs, and PPARγ agonists 
are administered as treatments for type 2 diabetes mellitus (17, 20). These different 
types of drugs only have antiinflammatory properties in common. Therefore, it is 
most likely that these drugs exert their inhibitory effect on high-fat diet–induced OA 
through suppression of low-grade systemic inflammation associated with obesity and 
metabolic stress. Indeed, both treatments resulted in decreased levels of human CRP, 
which served as a marker of inflammation in this study. This is in line with previously 
reported data demonstrating that statins reduce basal and IL-1β–induced human 
CRP expression independent of their cholesterol-lowering effect (12). This implies 
that systemic inflammatory factors play an important role in the development of 
high-fat diet–induced OA.
A primary role for inflammation in general in the pathogenesis of OA is also 
supported by the finding that a statin and a PPARγ agonist suppressed mechanically 
induced OA in animal models by interfering with local inflammatory processes. 
Intraarticular administration of mevastatin reduced inflammatory cell infiltration 
and matrix-degrading enzyme expression in a rabbit model of experimental OA (23). 
Furthermore, Boileau et al showed an inhibitory effect of pioglitazone (a PPARγ 
agonist) on the activation of signaling pathways of inflammation in a dog model of 
experimental OA (24). In addition to models of mechanically induced OA, Yudoh and 
Karasawa recently demonstrated significantly reduced cartilage degeneration due 
to statin treatment in STR/Ort mice, a strain that spontaneously develops OA (32). 
In vitro data suggest that statins and PPARγ agonists have several direct effects on 





































3 (MMP-3) expression in stimulated human OA chondrocytes and also inhibited 
apoptosis of synoviocytes. Furthermore, PPARγ agonists suppressed the expression 
of inducible nitric oxide synthase and MMP-13 in human chondrocytes as well as the 
expression of MMP-1 in human synovial fibroblasts (21, 22, 33, 34). Stimulation with 
IL-1 in these in vitro experiments suggests that induction of inflammatory pathways 
is important for these outcomes and explains the effect of statins and PPARγ agonists 
on these OA-related processes through their antiinflammatory action.
The adipokines leptin and resistin are important systemic factors that are 
associated with obesity and suggested to be involved in the development of OA (35). 
Griffin et al showed in leptin-deficient (ob/ob) and leptin receptor–deficient (db/db) 
mice that body fat adiposity in the absence of leptin signaling is insufficient to induce 
systemic inflammation and knee OA (36). Consistent with this, we recently showed 
that quality of adipose tissue (and not its mass) is linked to systemic inflammation 
status (37). This confirms that proinflammatory factors induced by fat gain are more 
important in our model than mechanical overload due to an increase in body mass, 
although previously an association was suggested between body mass and fat and 
the loss of cartilage matrix proteoglycans in C57BL/6 mice on a high-fat diet (38). 
The proposed proinflammatory effect of leptin would match very well with increased 
serum leptin levels in the high-fat diet model and the involvement of inflammation in 
high-fat diet–induced OA. However, conclusive evidence for this is lacking, since we 
found no correlation between severity of OA and circulating leptin levels at end point. 
Furthermore, rosuvastatin and rosiglitazone treatment did not reduce leptin levels, 
indicating that if leptin is involved, the inhibitory effect of these treatments is not 
by acting directly on leptin, but probably by influencing downstream inflammatory 
processes regulated by leptin.
Obesity is also associated with the development of insulin resistance (39). All 
mice developed higher insulin levels after switching to a high-fat diet except for 
those treated with rosiglitazone. The antidiabetic property of rosiglitazone is thereby 
confirmed in this model, but the insulin-lowering capacity is most likely not the cause 
of the suppressive effect seen on OA development. Since rosuvastatin-treated mice 
display insulin levels comparable to those in untreated mice, insulin resistance as 
part of the metabolic syndrome cannot be used to clarify the inhibitory effect of 
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Besides variation in body weight, the human CRP levels, which were used to 
monitor inflammation status, also varied between mice of the same group. The 
variation seen in our study is typical for human CRP–transgenic mice, and similar 
variation has been reported previously (40, 41). In several human studies, human CRP 
level is correlated with various features of OA, such as extent and severity of knee 
OA, knee pain or markers of local synovial inflammation, and knee OA progression. 
However, human CRP level is not associated with incidence of knee or hip OA when 
possible confounding factors such as body mass index are taken into account, 
suggesting that human CRP is not a functional protein in the onset of OA (42, 43).
In our study, we found a correlation between OA grade at end point and change in 
human CRP level 3 days after diet switch, which suggests that the responsiveness to a 
metabolic challenge can be used as a marker to estimate the individual susceptibility 
to developing OA later in life. Consistent with this, we showed that the acute 
response to high-fat diet–induced stress results in a transient inflammatory response 
that normalizes as soon as metabolically active organs have adapted their glucose 
and lipid metabolism (44). Indeed, after several weeks, human CRP levels decreased 
to baseline levels, and the correlation with OA grade was lost. Since only 9 male mice 
were in this group, an increased number should be investigated to confirm these 
results. Our finding of no correlation between human CRP level and OA when an 
inflammatory response was evoked by IL-1 suggests that metabolic stress–induced 
inflammation encompasses more inflammatory signaling routes than only those 
triggered by IL-1.
It is known that in different inbred strains, male mice have a higher susceptibility 
to developing OA than do female mice (45-47). Concordant with this, in our study 
only male mice developed substantial and severe OA characteristics after 38 weeks 
on a high-fat diet. Also, it is well established that female mice on the C57BL/6 
background are less sensitive to developing features of the metabolic syndrome 
(obesity, adiposity, metabolic inflammation, and the like) than are their male 
counterparts (48). Highlighting this is the fact that insulin levels, as a measure of 
diabetes, were very low in female mice compared to male mice on a high-fat diet. 
This indicates that metabolic stress is more important than age-dependent processes 





































The present study demonstrates that low-grade inflammation associated with 
obesity plays an important role in the development of high-fat diet–induced OA, 
since rosuvastatin and rosiglitazone suppress development of OA features via their 
antiinflammatory mode of action. Mechanical overload seems to be less important 
in the development of OA in this high-fat diet–induced disease model, since no 
correlation with body weight or body fat mass was observed. Individual susceptibility 
to a metabolic challenge may predict OA development at end point and needs to 
be further investigated. These findings suggest that the use of statins and PPARγ 
agonists could be a strategy for interfering with the progression of the disease, at 
least in those patients with metabolic disorders. Identification of the inflammatory 
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Objective Hypercholesterolemia, a risk factor for atherosclerosis (ATH), has been 
suggested to have a role in osteoarthritis (OA) development. To test this hypothesis, 
the effect of cholesterol and different cholesterol-lowering treatments on OA was 
investigated in a mouse model resembling human lipoprotein metabolism.
Methods Female ApolipoproteinE*3Leiden.human Cholesteryl Ester Transfer Protein 
mice received a western type diet (WTD) with 0.1% (w/w) cholesterol (LC), 0.3% 
(w/w) cholesterol alone (HC) or treated with 3 mg/kg/day atorvastatin or 0.3 mg/
kg/day ezetimibe. One group remained on chow (control). After 39 weeks, OA grades 
of the knees and the extent of ATH were determined. Plasma cholesterol levels were 
measured throughout the study.
Results LC and HC groups developed significantly more OA at the medial side than 
the control group in a dose-dependent manner. Atorvastatin but not ezetimibe 
treatment significantly suppressed OA development. As expected, features of ATH 
were significantly increased in the LC and HC groups compared to the control group, 
and suppressed by atorvastatin (48%) and ezetimibe (55%) treatment. There were 
significant correlations between the development of OA on the medial side of the 
joint and cholesterol exposure (r=0.4) or ATH features (r=0.3).
Conclusions Dietary cholesterol and accordingly increased plasma levels play a role 
in the development of OA. The correlation found between OA, cholesterol and ATH 
demonstrates that these variables are connected, but indicates the contribution 
of other ongoing processes in OA development. The suppressive effect on OA 
development of atorvastatin but not of ezetimibe, which had similar cholesterol 
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Osteoarthritis (OA) is a degenerative joint disease with major implications on the 
quality of life. Recently, various studies presented a relation between OA and the 
prevalence of metabolic syndrome (MetS) (1-3). MetS is generally considered a 
combination of obesity, hypertension, dyslipidemia and impaired glucose tolerance 
(4). Puenpatom et al demonstrated that prevalence of MetS was over twofold higher 
in the OA population and OA was associated with an increased risk of having MetS (5). 
These results have led investigators to contemplate common underlying pathologies 
in OA and MetS related diseases.
Related to MetS is hypercholesterolemia that can result as a consequence of 
abnormalities in the cholesterol uptake in the gut and/or improper regulation of 
plasma cholesterol levels. Interestingly, hypercholesterolemia was shown to be 
associated with generalized OA (6). Furthermore, serum cholesterol and triglycerides 
are linked with the incidence of bone marrow lesions, which are common in OA 
patients (7). Some studies indicate that cholesterol induces low grade inflammation 
in humans and in mice and that this is dependent on the amount of cholesterol 
in the diet (8, 9). Low grade inflammation is also designated to play a role in OA 
development, which suggests it could be the link between elevated cholesterol levels 
and OA (10). 
An extended exposure to increased cholesterol levels can lead to the development 
of atherosclerosis (ATH) (11, 12). The question is raised if ATH and OA are linked by 
common underlying mechanisms (13). This suggestion is strengthened by the finding 
that ATH was associated with OA in several joints in women (14, 15). Furthermore, 
it has been hypothesized that atheromatous vascular disease is linked to OA and 
is probably more involved in the progression of OA than in its initiation (16). It is 
unclear whether OA and ATH occur as concurrent diseases due to common etiology 
or are causally related (13). 
Cholesterol lowering interventions are used to prevent harmful consequences 
caused by high cholesterol exposure (e.g. ATH) (17). Statins, hydroxymethylglutaryl 
(HMG) Co-A reductase inhibitors, are commonly used and have been reported to 
possess pleiotropic effects independent of their cholesterol lowering capacity. 
Statins are also suggested to have important therapeutic value in the context of OA 





































action to that of statins, is ezetimibe which inhibits the uptake of cholesterol in the 
intestine.
Given the emerging evidence that in man cholesterol levels are linked to OA 
features, we questioned whether increased intake of cholesterol would be sufficient 
to induce OA. We used the ApolipoproteinE*3Leiden.Human Cholesteryl Ester 
Transfer Protein (APOE*3L.CETP) transgenic mouse which is a well-established 
model for hyperlipidemia and ATH and resembles human lipoprotein metabolism 
in contrary to wild type mice (21). Statin and ezetimibe treatments were included 
to further understand the contribution of cholesterol in the development of OA. 
The dosages of the treatments were chosen to result in similar plasma cholesterol 
levels as obtained in mice receiving low cholesterol concentrations in their diet. This 
enabled us to study the effects of the drug interventions on OA and ATH independent 
of but also in addition to their cholesterol lowering properties (22, 23).
Methods
Mice
Female APOE*3Leiden mice, characterized by an enzyme-linked immunosorbent 
assay (ELISA) for human APOE, were crossbred with human CETP transgenic mice 
which express CETP under control of its natural flanking regions in our animal facility 
to obtain heterozygous APOE*3L.CETP mice (24-28). Mice were housed in groups 
under standard conditions with a 12h light-dark cycle and had free access to water 
and food. Body weight (BW) and food intake were monitored during the study. 
Experiments were approved by the institutional Animal Care and Use Committee of 
TNO and were in compliance with European Community specifications regarding the 
use of laboratory animals.
 
Experimental design and diets
Mice (n=78) were fed standard lab chow (V1534 Ssniff Spezialdiäten GmbH, 
Germany) until the start of the study at the age of 10-16 weeks. At t=-4 weeks 66 
mice received a semi-synthetic western type diet (WTD) (AB diets, the Netherlands) 
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in moderately elevated plasma cholesterol levels of mean ± SD 10.1 ± 1.1 mmol/L. 
Twelve mice remained on chow (control group) (plasma cholesterol level mean ± SD 
3.5 ± 0.9 mmol/L). After 4 weeks (t=0) mice receiving LC (n=66) were randomized 
into 4 groups of 12 animals with on average comparable age, BW, plasma cholesterol 
and triglyceride levels. Of these 4 groups one continued on LC (LC group) and the 
others switched to a WTD containing 0.3% (w/w) cholesterol (high cholesterol HC 
group) or HC supplemented with 3 mg/kg/day (0.0036% (w/w)) atorvastatin (Lipitor, 
Pfizer, the Netherlands) (HC atorvastatin group) or 0.3 mg/kg/day (0.0003% (w/w)) 
ezetimibe (Ezetrol, OPG Pharma, the Netherlands) (HC ezetimibe group). Mice which 
not responded to the LC diet were sacrificed immediately (n=18). Atorvastatin and 
ezetimibe dosages were chosen to reduce plasma cholesterol to the same extent as 
levels in the LC group. Mice were sacrificed after 39 weeks (t=39), reaching an age of 
53-59 weeks.
Lipid and lipoprotein analysis
Blood samples were collected after 4h of food deprivation by tail incisions in EDTA 
tubes (Sarstedt, Germany) at t=-4, 0, 2, 6, 10, 14, 18, 22, 26, 30, 34 and 38 and by 
heart punction at t=39 weeks. After centrifuging for 10 minutes at 6000 rpm plasma 
was collected. Total plasma cholesterol (Roche Diagnostics, No-1489437) was 
determined immediately. For lipoprotein profiles, pooled plasma of each group was 
fractionated using an Äkta FPLC system (Pharmacia, the Netherlands) and analyzed 
for their cholesterol containing fractions. Thereafter plasma was stored at -80 °C. 
Total cholesterol exposure (mmol/l * time in weeks) was calculated for each mouse.
Plasma inflammation markers
Alanine Aminotransferase (ALT) was determined spectrophotometrically in pooled 
plasma samples at t=0, 18 and 38 weeks using a reflotron system (Roche diagnostics, 
USA). Serum Amyloid A (SAA) (Tridelta development, Ireland) (t=0, 18 and 38 weeks), 
E-selectin and monocyte chemoattractant protein-1 (MCP-1) (both R&D Systems Inc., 
USA) (t=39 weeks) levels were determined in the individual plasma samples by ELISA 
according to the manufacturers’ instruction. IL-1, IL-6, TNF-α and IFN-γ levels were 
determined in plasma samples (t=39 weeks) using multiplex analysis according to 





































Histological examination of OA and ATH 
The knee joints of the left hind limbs were fixed in formalin (Sigma-Aldrich, USA), 
decalcified in Kristensen solution (29), dehydrated and embedded in paraffin. Serial 
coronal 5 µm sections were collected and stained with hematoxylin, fast green and 
safranine-O and with hematoxylin, phloxine and saffron (HPS). Sections were scored 
by 2 independent observers, who were blinded for group assignment, at 6 locations 
in the joint; femoral condyle and tibia plateau at the lateral and medial side, trochlear 
groove and the patella (score 0-6) (30). The whole joint was scored following the 
guidelines of the OARSI grading system including cartilage structure, proteoglycan 
depletion and chondrocyte morphology (31).
Hearts were isolated, formalin-fixed, embedded in paraffin, sectioned and 
assessed for ATH features (Figure S1). ATH lesion areas were calculated and classified 
into five categories according to the American Heart Association (AHA) (32). Type 
I–III were classified as mild and IV–V lesions as severe lesions. For each mouse, the 
percentage of all lesions found in the respective categories were calculated (25). 
Statistical analysis
Data are presented as mean ± SD. Statistical differences were assessed using the 
non-parametrical Kruskal Wallis test followed by Mann Whitney U test (OA scores, 
ATH lesion area, total cholesterol exposure and MCP-1 and e-selectin levels). BW, 
cholesterol and SAA levels were tested with repeated measure analysis followed 
by Dunnett T3 post hoc test. OA scores, ATH lesion area and cholesterol exposure 
correlations were calculated with the Spearman Correlation test. A partial correlation 
was performed for OA scores and ATH lesion area after correction for cholesterol 
exposure. Inter-observer correlation for OA scores was measured with Spearman 
Correlation test. SPSS 20.0 for Windows (SPSS, USA) was used for statistical analyses. 








































Every 2 weeks, BW of all mice were measured and revealed no significant differences 
between groups during the course of the study (Figure 1A).
To assess the effects of cholesterol intake, plasma cholesterol levels were 
determined every 4 weeks (mmol/l). The LC and HC groups had significantly higher 
cholesterol levels over time than the control group (both p<0.001) (Figure 1B). This 
was confirmed by the total cholesterol exposure (mmol/l * time in weeks) (Figure 
1C); the LC group had 3.1 and the HC group had 5.6 times more cholesterol exposure 
than the control group (both p<0.001).
Elevated cholesterol levels due to HC were significantly reduced by atorvastatin 
and ezetimibe treatment (both p<0.001) to similar levels as the LC group (Figure 1B). 
Atorvastatin reduced the total cholesterol exposure levels by 35% and ezetimibe 
by 38% (both p<0.001), to a level comparable as in the LC group (Figure 1C). In 
general, lipoprotein profiling revealed that the reduction in total cholesterol by the 
atorvastatin and ezetimibe treatments was mainly confined to the (very-)low-density 
lipoprotein (VLDL)/LDL fractions which is demonstrated by representative data 
obtained at t=34 (Figure 1D).
Inflammation markers
The acute phase protein SAA, the liver damage marker ALT, the adhesion molecule 
E-selectin and the pro-inflammatory chemokine MCP-1 were measured as functional 
markers for inflammation. SAA levels were higher in the LC and HC compared to 
the control group during the course of the study (non-significant). The LC and HC 
groups showed a tendency for higher ALT levels, but significance could not be tested 
since this parameter could only be measured in pooled plasma. At end-point, MCP-
1 levels in the LC and HC group were significantly higher than in the control group 
(p<0.001). E-selectin levels were significantly higher in the HC group than in the 
control group(p<0.001).
After atorvastatin and ezetimibe treatment, mice had lower SAA and ALT levels 





































significantly reduced E-selectin levels (p<0.01). MCP-1 levels were not affected by the 
treatments (Table 1).
IL-1, IL-6, TNF-α and IFN-γ levels in the plasma samples at end point were below 
the lowest level of detection in the multiplex assays.
Figure 1. Characteristics of APOE*3Leiden.CETP mice on a control, low and high cholesterol 
diet A. Body weight (grams), B. Total plasma cholesterol levels (mmol/L), C. Total cholesterol 
exposure (mmol/L*weeks) in the complete study, D. Representative cholesterol distribution 
after lipoprotein separation (mmol/L) at t=34 weeks. Fractions 4-15 contain the ApoB 
containing lipoproteins (VLDL/LDL) and fractions 16-24 contain the HDL particles. Control 
(n=12), low cholesterol (LC) (n=10), high cholesterol (HC) (n=12) or HC group treated with 
atorvastatin (n=12) or ezetimibe (n=11) (HC atorvastatin and HC ezetimibe), ###p<0.001 vs 
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t=0 t=18 t=38 t=0 t=18 t=38 t=39 t=39
Control 4.6 (4.6) 2.3 (0.9) 7.0 (4.5) 59.7 56.9 51.3 40.6 (9.4) 26.1 (7.7)
LC 3.4 (0.8) 3.1 (1.0) 7.4 (4.2) 43.9 68.3 169 41.8 (6.8) ** 45.5 (12.2) ###
HC 3.75 (0.61) 5.9 (2.1) 9.1 (5.0) 50.2 109 192 52.9 (7.3) ### 51.4 (11.0) ###
HC Atorvastatin 3.9 (3.2) 3.3 (1.2) 6.4 (1.8) 48.9 64.5 164 42.9 (8.2) ** 51.4 (17.4) ###
HC Ezetimibe 3.5 (3.0) 3.0 (0.9) 8.6 (5.4) 40.3 52.2 174 43.9 (12.0) ** 46.2 (15.2) ###
Serum amyloid A (SAA) and Alanine Aminotransferase (ALT) levels at t=0, t=18 and t=38 weeks 
and E-selectin and monocyte chemoattractant protein-1 (MCP-1) levels at t=39 weeks. Data 
are indicated as mean (SD). SAA, E-selectin and MCP-1 levels were determined in individual 
plasma samples. ALT levels were measured in pooled plasma samples. Control (n=12), low 
cholesterol (LC) (n=10), high cholesterol (HC) (n=12) or HC treated with atorvastatin (n=12) or 
ezetimibe (n=11) (HC atorvastatin and HC ezetimibe) groups. ###p<0.001 vs control, **p<0.01 vs 
HC.
Osteoarthritis development
The knee joints were analyzed to assess the effect of increased dietary cholesterol 
on OA development (Inter observer rate R=0.8, p<0.001). Representative histological 
pictures are presented in Figure 2A. Mice developed significantly more OA features 
at the medial side of the joint in the LC (p=0.03) and HC (p=0.01) groups than in the 
control group (Figure 2B). No effects of increased cholesterol intake were seen on 
the lateral side or on the trochlear groove. When giving an integrated score of the 
entire knee joint (including all components, i.e. total OA grade), effects of increased 
cholesterol intake on OA development were also observed, although not significant 
(Table 2).
To investigate whether cholesterol-lowering drugs can diminish the development 
of OA, treatment with atorvastatin or ezetimibe was included. Atorvastatin 
suppressed the development of OA at the medial side significantly compared to 
the HC group (p=0.046), whereas ezetimibe did not have this effect (Figure 2A). No 
significant effects of these treatments were seen on the lateral side, the trochlear 





































Figure 2. Effect of dietary cholesterol on osteoarthritis (OA) development in the knee joints 
of APOE*3Leiden.CETP mice A. Representative pictures of hematoxylin, fast green and 
safranine-O stained medial knee joints. Scale bar indicates 100 µm, B. Sum total of the OA 
grades at the medial femur and tibia of the knee joint. Each dot is an individual mouse. Line 
indicates the mean ± SD. Control (n=12), low cholesterol (LC) (n=10), high cholesterol (HC) 
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Table 2. Osteoarthritis (OA) grades 
Control LC HC HC Atorvastatin HC Ezetimibe
Medial Femoral condyle 0.73 (0.37) 1.20 (0.49) # 1.63 (1.23) # 0.84 (0.34) ^ 1.36 (1.57)
Tibia plateau 1.29 (0.42) 1.51 (0.30) 2.04 (1.02) # 1.46 (0.54) 1.85 (1.26)
Total 2.02 (0.64) 2.71 (0.65) # 3.67 (2.17) # 2.30 (0.73) * 3.22 (2.80)
Lateral Femoral condyle 1.72 (0.26) 1.68 (0.35) 1.33 (0.61) 1.45 (0.47) 1.49 (0.67)
Tibia plateau 1.61 (0.55) 1.59 (0.67) 1.81 (0.81) 1.83 (0.94) 1.70 (0.53)
Total 3.33 (0.76) 3.26 (0.94) 3.15 (0.97) 3.28 (1.27) 3.19 (1.03)
Patella Patella 0.83 (0.71) 1.20 (1.69) 1.26 (1.42) 1.09 (0.83) 1.09 (1.01)
Trochlear groove 1.01 (0.61) 1.11 (1.14) 1.23 (0.88) 0.98 (0.56) 1.24 (0.89)
Total OA grade 5.85 (1.57) 7.00 (2.96) 7.35 (3.46) 5.68 (2.03) 7.11 (3.71)
OA grades were scored at the medial, lateral side and patella in control (n=12), low cholesterol 
(LC) (n=10), high cholesterol (HC) (n=12) or HC treated with atorvastatin (n=12) or ezetimibe 
(n=11) (HC atorvastatin and HC ezetimibe) groups. Data are indicated as mean (SD). #p<0.05 vs 
control; *p<0.05, ^p<0.1 vs HC.
Atherosclerosis development
The origin of the aorta in the hearts were analyzed for ATH features. Regular ATH 
studies in APOE*3L.CETP mice last on average 19-21 weeks (21, 24, 25), however in 
this study the exposure to high cholesterol was almost twice as long. After 39 weeks 
the LC and HC groups developed severe ATH in the aortic root (Figure 3A). The total 
lesion area per cross-section was 33.5 time higher in the LC group and 91.8 times 
higher in the HC group than the control group (both p<0.001) (Figure 3B). The LC and 
HC group had significantly more severe lesions than the control group (both p<0.001) 
(Figure 3C).
Atorvastatin and ezetimibe treatment led to significantly reduced lesion areas 
compared to the untreated HC group (48% and 55% respectively; both p<0.001) 
(Figure 3B). Mice receiving atorvastatin treatment had significantly less severe (V-IV) 






































Figure 3. Effect of dietary cholesterol on atherosclerotic development in the aortic root area 
of APOE*3Leiden.CETP mice A. Representative pictures of atherosclerotic lesions in the root 
stained with hematoxylin, phloxine and saffron (HPS). Scale bar indicates 100 µm, B. Total 
lesion area per cross section * 1000 µm2, C. Lesion severity as a percentage of all lesions (mild: 
I-III and severe: IV-V). Control (n=12), low cholesterol (LC) (n=10), high cholesterol (HC) (n=12) 
or HC group treated with atorvastatin (n=12) or ezetimibe (n=11) (HC atorvastatin and HC 
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Correlations
To explore how and to which extent OA was related to cholesterol exposure and 
ATH lesion area, linear regression analysis was performed. OA grades at the medial 
side of the knee joint in the control, LC and HC groups were significantly associated 
with total cholesterol exposure (R=0.43; p<0.01) (Figure 4A). Cholesterol exposure 
levels of each mouse in the control, LC and HC group were strongly and significantly 
correlated with the corresponding lesion area (R=0.91; p<0.001) (Figure 4B), and 
therefore it was consistent that lesion area and OA grades were also significantly 
correlated (R=0.34; p=0.03) (Figure 4C). To evaluate the contribution of ATH features 
in addition to cholesterol exposure, partial correlation correcting for cholesterol 
exposure was performed and revealed no significant correlation between ATH 





































Figure 4. Overview of correlations in the control, low cholesterol (LC) and untreated high 
cholesterol (HC) groups A. OA grade (sum total of the OA grades at the medial femur and 
tibia of the knee joint) and cholesterol exposure (mmol/L*weeks), B. Cholesterol exposure 
(mmol/L*weeks) and atherosclerosis (ATH) development (total lesion area/cross-section 
(*1000 µm2)), C. OA grade (sum total of the OA grades at the medial femur and tibia of the 
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Discussion
There is currently mounting evidence that the MetS and OA are associated with one 
another (2, 3). Hypercholesterolemia is related to MetS and a risk factor for ATH. 
Associations between OA and ATH suggest similarities in their underlying pathologies 
(11, 15, 33, 34). In this study using the APOE*3L.CETP mouse model, we demonstrate 
that hypercholesterolemia indeed plays a role in the development of OA since an 
increased intake of cholesterol led to more severe OA features in the knee joints. 
Furthermore, a significant correlation between cholesterol exposure and OA features 
on the medial side of the knee joint indicates that high levels of cholesterol in the 
blood contribute to the OA process. However, correlation coefficients suggest 
that other processes, evoked by the intake of cholesterol, are also involved in the 
pathogenesis of OA. The suppressive effect on OA development by atorvastatin 
but not by ezetimibe, which had similar effects on cholesterol exposure levels, 
corroborates these findings.
Impaired lipid metabolism has been suggested an important factor in OA 
development. We used the APOE*3Leiden.CETP mice as translational model for 
human lipoprotein metabolism and development of ATH. To our knowledge this is 
the first study in which the effect of solely cholesterol, without interference of other 
variables such as BW, on OA development has been investigated. Since elevated 
cholesterol intake led to more advanced OA features, these data suggest a role for 
cholesterol in OA development. Compared to other spontaneous models, such as 
high fat diet (HFD)-induced OA, the development of OA is mild, although it is difficult 
being conclusive due to differences in strains, gender, and lengths of the studies (10, 
35-37). The differences were only seen at the medial side of the joint which is known 
to be most susceptible in mice models and therefore in line with our expectations 
(38).
Whether the development of OA after cholesterol intake is due to a direct effect 
of cholesterol (local effects), other mechanisms induced by cholesterol (systemic 
effects), or a consequence of ATH is uncertain. With respect to local effects, several 
mechanisms of altered lipid mechanisms on OA development are suggested. 





































cholesterol efflux is impaired, resulting in a toxic accumulation of lipid droplets in the 
chondrocyte (39, 40). In addition, an association of OA pathogenesis with SREBP-2, a 
gene that plays a key role in cholesterol homeostasis, was demonstrated (41). These 
findings suggest a direct role for cholesterol in triggering degenerative processes in 
the cartilage by altered cholesterol homeostasis in the chondrocytes. However, in 
our in vivo mouse model only a moderate correlation between plasma cholesterol 
exposure and OA development was observed which suggests that cholesterol is not 
solely responsible for the development of OA. Altered underlying systemic processes 
such as inflammation that are the result of increased cholesterol load, may therefore 
be more relevant. This is substantiated by the fact that SAA, ALT, E-selectin and MCP-
1 levels in the mice were increased when fed a cholesterol diet. Kleemann et al. 
performed a gene expression analysis which indicated 4 key inflammatory pathways 
consisting of IFNγ, TNFα, IL-1 and platelet derived growth factor (PDGF) to play a 
central role in the evolution of cholesterol-induced inflammation in the liver (8). 
These pathways are also critical for lesion development in the vessel wall and known 
to be important in OA development (42). Circulating levels of cytokines thought to 
be important in OA, e.g. TNFα. IFNγ, IL-6 and IL-1 were not detectable in this study 
which is consistent with previous findings in our lab with these transgenic mice on a 
cholesterol diet (unpublished data).
Alterations due to ATH may provide an alternative explanation for the 
development of OA in this model. For example, effects of a reduced blood flow in 
the small vessels in the subchondral bone may modify the cartilage homeostasis 
and cause OA changes (7, 13, 14, 16). This notion is supported by analysis of human 
data that revealed a significant association between intima media thickness and 
knee OA after adjustment for e.g. cholesterol levels (14). Moreover, hand OA was 
linearly associated with ATH features after adjustment for potential confounders 
(15). In our model, the lack of correlation between OA and ATH, when corrected 
for cholesterol exposure, debilitate ATH as main driving force for OA. This is further 
substantiated by the fact that ezetimibe, in contrast to atorvastatin, did not led 
to significant suppressive effects on OA development whereas these drugs had 
comparable effects on plasma cholesterol levels and ATH characteristics. Atorvastatin 
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inflammatory immunomodulation, plaque stabilization, decreased activation of the 
blood coagulation cascade, and inhibition of platelet aggregation which may be 
responsible for the different effect of atorvastatin compared to ezetimibe (43). In 
a previous study, we have shown that rosuvastatin suppressed the development of 
HFD-induced OA through its anti-inflammatory capacities (10). Moreover, it has been 
shown that intraarticular administration of mevastatin reduced inflammatory cell 
infiltration and matrix-degrading enzyme expression in a rabbit model of experimental 
OA indicating local effects of atorvastatin (19, 20). Our data suggest that statins may 
be an important candidate for the management of OA and additional studies are 
warranted.
In conclusion, elevated levels of cholesterol play a role in OA as mice receiving 
cholesterol in their diet develop OA features on the medial side of the knee joint. The 
moderate correlation between OA and cholesterol exposure suggests that processes 
independent of cholesterol exposure also contribute to development of OA features. 
This is further supported by the differences in effect of atorvastatin and ezetimibe on 
OA. Both drugs reduced cholesterol levels to the same extent, but only atorvastatin 
significantly diminished OA severity which may be attributed to its anti-inflammatory 
properties. This study supports the notion that components related to MetS such as 
hypercholesterolemia could significantly contribute to the development, progression 







































Figure S1. Representative photos of consecutive slices used for quantification of 
atherosclerosis (ATH). Valves were used as anatomical landmarks to start quantification of ATH 
development as indicated by arrows. Once the aortic root was identified by the appearance of 
aortic valve leaflets, serial cross-sections (5 µm thick with intervals of 50 µm) were collected 
and stained with hematoxylin, phloxine and saffron. For each mouse, the lesion area (as 
illustrated in photo 4) was measured in 4 subsequent sections (three segments/section). 
Therefore, ATH development area was measured over a length of 150 µm in the aortic origin. 
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Objective: Obesity, a major risk factor for OA, has been proposed to induce an 
inflammatory component in the pathogenesis of osteoarthritis (OA). We aimed to 
assess high fat diet (HFD)- induced OA development in APOE*3Leiden.cholesteryl 
ester transfer proteïne (CETP) mice, a mouse model with a human-like lipoprotein 
metabolism.
Methods: Male APOE*3Leiden.CETP mice (n=150) were switched to a HFD at the 
start of the study. After a 12 weeks run-in period, mice were matched based on 
body weight, plasma cholesterol, triglycerides and insulin levels in 8 different groups 
(n=12/group); 1 HFD control group, a HFD group which was switched back to a chow 
diet after 22 weeks, 2 HFD groups treated with rosuvastatin from either t=12 or 22 
weeks onward, 2 HFD groups treated with fenofibrate from either t=12 or t=22 weeks 
onward, 1 HFD group receiving caspase-1 inhibitor from 14 weeks onward and a group 
of low responders on HFD (with respect to above-mentioned parameters). A group 
receiving control chow diet (n=12) was included as well. All mice were sacrificed 32 
weeks after the start of the study and knee joints were histologically assessed for OA 
development. Serum amyloid A (SAA) levels in the plasma at the start of the study 
were measured as marker for systemic inflammation.
Results: In contrary to a previous study, OA grades in the HFD group were low. 
Furthermore, the HFD group tended to display a lower overall OA grade than the 
control group (p=0.081). Low responders on a HFD as well as mice switched from 
HFD to a chow diet developed OA features to a comparable extent as the high 
responders. There was no significant effect of the various interventions on OA grades 
compared to the untreated HFD group. No anomalies were seen on body weight, 
plasma cholesterol and triglycerides levels. SAA levels were highly variable at the 
start of the study.
Conclusion: These results indicate that improved understanding of the susceptibility 
of APOE*3Leiden.CETP mice strain towards OA development is necessary to 
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The prevalence of obesity is worldwide rapidly accumulating (1). Severe medical 
consequences as well as negative effects on the quality of life due to obesity 
are widely recognized (2). Obesity is an important component of the metabolic 
syndrome and a major risk factor for the development of osteoarthritis (OA) (3, 4). 
Since recently, no longer only the mechanical forces due to obesity are considered 
as instigator of OA but also the inflammatory responses triggered by obesity are 
believed to be important in the development (5-7). This was confirmed in a previous 
study in which we demonstrated in a high fat diet (HFD)-induced OA mouse model 
that the metabolic stress response played a major role in the development of OA 
instead of body weight. In the same study, treatment with rosuvastatin (a cholesterol 
lowering intervention) or rosiglitazone (peroxisome proliferator activator receptor 
(PPAR) gamma agonist, anti-diabetic drug) inhibited the development of OA possibly 
by their anti-inflammatory mode of action (8). This provided the foundation for 
further investigation into HFD-induced OA.
The apolipoprotein E*3Leiden.human Cholesteryl Ester Transfer Protein 
(APOE*3Leiden.CETP) transgenic mouse is a model which resembles human 
lipoprotein metabolism and is sensitive to lipid modulating therapies in contrary to 
wild type mice (9-11). Feeding a HFD to these mice leads to a profile of anomalies 
quite similar to those that are present in the majority of the patients having metabolic 
syndrome (12). In an unpublished study which was designed for lipid research 
purposes we found that APOE*3Leiden.CETP mice receiving a HFD and fructose in 
their drinking water developed severe features of OA. Moreover, we observed a 
strong inhibitory effect on OA development when mice were treated with fenofibrate 
(figure 1). Fibrates are agonists for the PPAR-α receptors and used in the clinic as drugs 
to reduce plasma triglycerides and cholesterol levels (13). Fibrates are, like statins, 
recognized for their pleiotropic effects (14). With respect to OA it has been shown 
in in vitro experiments that a PPAR-α agonist counteracts IL-1-induced proteoglycan 
degradation and increases MMP-activities in rabbit articular chondrocytes (15). 
Furthermore, Clockaerts et al. showed that a PPAR-α agonist inhibited inflammatory 
and destructive responses in human OA cartilage explants, while collagen type II or 
aggrecan mRNA expression remained unaffected (16). In addition, PPAR-α agonists 
have an inhibitory effect on inflammatory cytokines in infrapatellar fat pad explants 





































Figure 1. OA grades of male APOE*3Leiden.CETP mice included in a study designed for lipid 
research purposes. Mice received high fat diet (HFD) for 32 weeks or HFD supplemented with 
0.0212% w/w fenofibrate for 9 weeks. Fructose (10%) was added to the drinking water during 
the treatment period. Each point represents the value of an individual mouse. Line indicates 
mean ± SEM (n=8/group).
As mentioned, statins proved to inhibit the development of OA in a HFD-induced 
OA mouse model (8). Statins are HMG Co-A reductase inhibitors and used to reduce 
serum cholesterol levels in humans. There are indications from several in vitro and in 
vivo studies that statins have beneficial effects on the development of OA, probably 
by their anti-inflammatory mode of action (18-22). In an epidemiological study statin 
use was associated with more than 50% reduction in overall progression of knee OA 
(23). These findings are promising and warrant further investigation of fibrates and 
statins as potential therapeutic strategies for OA.
The pro-inflammatory cytokine interleukin (IL)1-β is suggested to have an 
important role in OA pathogenesis (24-26) as well as in obesity (27). IL-1β is 
synthesized as an inactive precursor and needs to be converted by the enzyme 
caspase-1 to become active. Caspase-1 itself requires activation via a molecular 
platform called the inflammasome (28). The activation of inflammasome-mediated 
caspase-1 plays a key role in the enhanced inflammatory state characteristic of 
obesity and has a central role in the pathogenesis of type 2 diabetes (27). Although 
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of any inflammasome activity (29), the role of inflammasome in relation to obesity-
induced OA merits more investigation.
A more pragmatic way to intervene in the OA process are weight-losing programs. 
Increasing evidence exists that irrespective of the weight-loss method (e.g. exercise, 
diet, bariatric surgery), a reduced body fat contributes to a reduced OA development 
(30). In relation to inflammation, substantial weight loss in obese subjects with type 
2 diabetes was shown to reduce expression levels of IL-1β and inflammasome in 
adipose tissue (31). Furthermore, weight loss decreases leptin and C-reactive protein 
(CRP) levels, reduces the synthesis of IL-6 and tumor necrosis factor (TNF)-α and 
increases the production of anti-inflammatory cytokines by subcutaneous adipose 
tissue (32, 33). These biochemical changes would, beside the reduction of mechanical 
stressors, attribute to improved clinical outcome of OA.
The aim of this study was to assess the sensitivity of the APOE*3Leiden.CETP 
mouse as a model for HFD-induced osteoarthritis (OA) as a more predictive model 
for the human situation. Furthermore, we aimed at a better understanding of the 
mechanisms underlying HFD-induced OA to identify new potential targets for therapy. 
Different treatment regimens (early versus late) with rosuvastatin and fenofibrate 
were included to evaluate the efficacy of these drugs at different stages of the OA 
process. To investigate whether the inflammasome plays a role in HFD-induced OA 
a treatment with caspase-1 inhibitor was included. At last, we examined if losing 
weight at a stage where there is already significant progression of OA, could prevent 
further advancing of or delay the process of OA development.
Methods 
Mice
Male APOE*3Leiden mice, characterized by an enzyme-linked immunosorbent assay 
(ELISA) for human APOE, were crossbred with human CETP transgenic mice which 
express CETP under control of its natural flanking regions in our animal facility to 
obtain heterozygous APOE*3Leiden.CETP mice (10-12). Mice were housed in groups 
under standard conditions with a 12 h light-dark cycle and had free access to water 





































received a standard lab chow (V1534 Ssniff Spezialdiäten GmbH, Germany ) until the 
start of the study at the age of 10-16 weeks (t=0 weeks). Experiments were approved 
by the institutional Animal Care and Use Committee of TNO and were in compliance 
with European Community specifications regarding the use of laboratory animals.
Pilot Study
A pilot study ran 5 weeks ahead of the main study to investigate OA development 
over time. APOE*3Leiden.CETP mice (n=27) were switched to a HFD (60% kcal from 
fat; Research Diets Inc. art. No. 12492) at the start of the study. After 12 weeks mice 
were matched based on BW, plasma cholesterol, triglycerides (TG) and insulin levels 
in 4 different groups (n=5/group, group 1-4) and low responders with respect to the 
above-mentioned parameters were removed from the study. Groups were sacrificed 
after either 12, 16, 20 or 24 weeks.
Main study
APOE*3Leiden.CETP mice (n=150) were switched to a HFD at t=0 weeks. After a 12 
weeks run-in period (t=12), mice were matched based on BW, plasma cholesterol, 
TG and insulin levels in 8 different groups (n=12/group) and low responders were 
removed from the study, except for a group of n=12 mice that continued on HFD 
(HFD Low Responders) to investigate whether the low response on above-mentioned 
parameters is indicative for less OA progression. All other groups continued on HFD 
with or without treatment (HFD), except for one group (HFD_Chow) which was 
switched back to standard lab chow after 22 weeks (t=22 weeks). Two groups received 
a HFD supplemented with 0.005% w/w rosuvastatin (Provisacor®, Astrazeneca, 
Zoetermeer, the Netherlands) in which the first group received rosuvastatin from 
12 weeks onward (HFD + Rosu t=12) while the other received this drug from 22 
weeks onward (HFD + Rosu t=22). The same treatment schedule was applied for 2 
groups receiving HFD supplemented with 0.0212 % w/w fenofibrate (art no F6020, 
Sigma-Aldrich, St. Louis, USA) (HFD + Feno t=12 and HFD + Feno t=22). Furthermore, 
one group received a daily intra-peritoneal (i.p) injection with 10 mg/kg caspase-1 
inhibitor (AC-YVAC-CMK art.no. N-1330, Bachem, Bubendorf, Switzerland) dissolved 
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of n=12 mice received standard lab chow diet until the end of the study (Control). All 
mice were sacrificed after 32 weeks (t=32).
Cholesterol, triglyceride and insulin analyses
At t=12, 16, 20, 24, 28 and 32 weeks blood was collected 4 hours after food 
deprivation by tail vein incision to determine plasma levels of cholesterol and TG. 
Total plasma cholesterol (Roche Diagnostics, No-1489437) and TG (Roche diagnostics, 
No-1488872) levels were determined immediately after plasma collection to avoid 
influence of freeze-thawing on these parameters. Insulin was measured at t=12 for 
randomization purposes using an immunoassay ((Cat. no. 10-1113-01, Mercodia, 
Spain). Assays were performed according to the manufacturers’ instruction.
Serum Amyloid A analysis
Serum Amyloid A (SAA), an acute phase protein, was determined in the individual 
plasma samples collected at the start of the main study (t=0) by an ELISA (tridelta 
development, Ireland, distributed by Invitrogen) according to the manufacturers’ 
instruction.
Histopathology
All mice were sacrificed and the knee joints of the hind limbs were fixed in a 10% 
formalin neutral buffer solution (Sigma-Aldrich), decalcified in Kristensen’s solution 
(34), dehydrated and embedded in paraffin for histological analysis. Serial coronal 
5 µm sections were collected throughout the patella, medial and lateral side of the 
left knee joint. Sections were stained with hematoxylin, fast green and safranin O as 
well as with hematoxylin, phloxine and safran (HPS). Two sections per mouse were 
scored in a blinded fashion by 2 observers. The joint as a whole was scored following 
the international guidelines of the OARSI histological grading system. Briefly this 
scoring system is based on a combined assessment of severity (“grade 0; surface and 
cartilage intact” – “grade 6; deformation”) and extent (“stage 0; no OA activity” – 
“stage 4 >50% OA activity”) of OA in the articular cartilage (grade x stage, total score 
of 24)(35). In addition, 6 locations in the joint; femoral condyle and tibia plateau at 







































Data are presented as mean ± standard deviation (SD) unless stated otherwise. All 
statistical analyses were performed using the SPSS 17.0 statistical software package 
for Windows (SPSS Inc. Chicago, USA). Statistical differences were assessed using the 
non-parametrical Kruskal Wallis test followed by the post hoc Mann Whithey U test 
or the parametrical (repeated measures) ANOVA test followed by Dunnett’s post hoc 
tests. For statistical analysis the study was divided according to the various research 
questions in HFD versus Control or HFD_Chow, HFD Low Responders versus HFD, or 
HFD + Rosu t=12/22, HFD + Feno t=12/22 versus HFD or HFD + Casp.Inh. versus HFD. 
P<0.05 was considered statistically significant.
Results
Pilot study
BW, plasma cholesterol and TG levels were assessed during the study. All parameters 
increased gradually (Table 1). Mice were sacrificed at t=12, 16, 20 and 24 weeks on 
HFD to investigate the development of OA in the knee joint over time. After 12 weeks 
on a HFD, the OA score was relatively homogeneous. The longer the mice received a 
HFD, the more variation in OA score was observed (Figure 2A). Based on the severity 
of OA score, it was decided to start the late treatments in the main study at t=22 
weeks and to run the main study till 32 weeks. Plasma SAA levels at the start of the 
study were comparable between the different pilot groups with an average of 29.6 ± 
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Table 1. Body weight, plasma cholesterol and triglyceride levels of APOE*3Leiden.CETP mice 
in the pilot study.
 t=12 t=16 t=20 t=24
































































Body weight (BW), plasma cholesterol (Chol) and triglycerides (TG) levels of the different 
groups of APOE*3Leiden.CETP mice in the pilot study. Data are indicated as mean(SD)at t=12, 
16, 20 and 24 weeks. BW in grams, Chol en TG in mmol/L.
Figure 2. Osteoarthritis (OA) grades and Serum Amyloid A (SAA) levels A. Time course 
of OA development and B. Serum amyloid A (SAA) levels at the start of the study (t=0) in 
APOE*3Leiden.CETP mice on a high fat diet (HFD) in the pilot study. Groups were sacrificed 
after t=12, 16, 20 and 24 weeks (group 1-4). Each point represents the value of an individual 







































BW of the mice in the HFD group were significantly higher than those of mice in the 
control group during the course of the study (t=12 till t=32 weeks) (HFD vs Control 
p<0.001) (Figure 3A). A tremendous effect on BW was observed when the mice were 
switched from a HFD to a control chow diet at t=22 weeks. Within 6 weeks after the 
diet switch BWs of these mice were comparable to mice which were continuously fed 
a chow diet (HFD_Chow vs HFD p<0.001). Mice in the low-responder group gained 
more BW than the chow group, but never reached BW of the HFD group (HFD Low 
Responders vs HFD p<0.001). Rosuvastatin and fenofibrate treatment had no effect 
on BW (Figure 3B). BW was also not affected by a treatment with caspase-1 inhibitor 
(Figure 3C).
To evaluate the effects of a HFD-intake plasma cholesterol and TG levels were 
determined every 4 weeks. Plasma cholesterol levels in the HFD group were 
significantly higher than in the control group (HFD vs Control p<0.001) (Figure 4A). 
No such significant effect was observed for the TG levels, which already reached 
substantial levels in the control group (Figure 4D). A switch back from a HFD to a 
control chow diet decreased cholesterol levels immediately, returning to almost 
the levels in the control group (HFD_Chow vs HFD p=0.002). This was accompanied 
by a reduction in TG levels. The HFD Low Responder group had significantly lower 
cholesterol (p<0.001) and TG (p<0.01) levels than the HFD group. Rosuvastatin, 
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Figure 3. Body weight (BW). Time course of BW of APOE*3Leiden.CETP mice in the A. chow 
(Control), high fat diet (HFD), HFD_Chow and HFD Low Responders groups, B. HFD, HFD treated 
with rosuvastatin started from t=12 or t=22 onwards (HFD + Rosu t=12/ 22) and HFD treated 
with fenofibrate started from t=12 or t=22 weeks onwards (HFD + Feno t=12/22) groups and C. 
HFD and HFD treated with caspase-1 inhibitor (HFD Casp.inh.) groups. Each point represents 
the mean of the group (Control, HFD, HFD_Chow, HFD Low Responders, HFD + Rosu t=12/22, 
HFD + Feno t=12: n=12/group, HFD + Feno t=22 and HFD Casp.Inh.: n=11/group).***P<0.001 vs 





































Figure 4. Plasma cholesterol en triglycerides (TG) levels. Time course of plasma cholesterol 
(mmol/L) and triglycerides (mmol/L) levels of APOE*3Leiden.CETP mice in the chow (Control), 
high fat diet (HFD), HFD_Chow and HFD Low Responders groups (A,D) or the HFD, HFD treated 
with rosuvastatin started from t=12 or t=22 weeks onwards (HFD + Rosu t=12/22) and HFD 
treated with fenofibrate started from t=12 or t=22 weeks onwards (HFD + Feno t=12/22) 
groups (B,E) or HFD and HFD treated with caspase-1 inhibitor (HFD Casp.inh.) groups (C,F). 
Each point represents the mean (Control, HFD, HFD_Chow, HFD Low Responders, HFD + Rosu 
t=12/22, HFD + Feno t=12: n=12/group, HFD + Feno t=22 and HFD Casp.Inh.: n=11/group).***P
<0.001,**p<0.01,*p<0.05 vs HFD and ###p<0.001 vs Control.
OA grades
The knee joints of the APOE*3Leiden.CETP were analysed for the effects of HFD as 
well as different interventions on the development of OA. Surprisingly, the control 
group tended to display an higher overall OA grade than the HFD group (Control 
vs HFD p=0.081). The HFD Low Responders group as well as the group which was 
switched from a HFD to a control diet halfway the study had no significantly different 
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various treatments on HFD-induced OA were observed (Figure 5BC). With respect to 
the individual components of the knee joint (femoral condyle and tibia plateau at the 
lateral and medial side, trochlear groove and the patella) no significant effects were 
observed either (data not shown).
Figure 5. OA development in the hind knee joint of APOE*3Leiden.CETP mice in the main study 
(t=32 weeks). An overall OA grade was determined in the A. chow (Control), high fat diet (HFD), 
HFD_Chow and HFD Low Responders group, B. HFD, HFD treated with rosuvastatin started 
from t=12 or t=22 weeks onwards (HFD + Rosu t=12/22) and HFD treated with fenofibrate 
started from t=12 or t=22 weeks onwards (HFD + Feno t=12/22) groups and C. HFD and HFD 
treated with caspase-1 inhibitor (HFD Casp.inh.) group. Each point represents the value of an 
individual mouse (Control, HFD, HFD_Chow, HFD Low Responders, HFD + Rosu t=12/22, HFD 






































Serum Amyloid A levels
As there were unexpected observations with regard to OA grades we assessed the 
level of inflammation by measuring the acute phase protein SAA in plasma samples 
collected at the start of the study (t=0 weeks). Mice in all groups demonstrated a 
great variation in their SAA levels (Figure 6).
Figure 6. Serum Amyloid A levels (SAA) in the APOE*3Leiden.CETP mice at the start of the 
study (t=0 weeks). A. chow (Control), high fat diet (HFD), HFD_Chow and HFD Low Responders 
group, B. HFD, HFD treated with rosuvastatin started from t=12 or t=22 weeks onwards (HFD 
+ Rosu t=12/22) and HFD treated with fenofibrate started from t=12 or t=22 weeks onwards 
(HFD + Feno t=12/ 22) groups and C. HFD and HFD treated with caspase-1 inhibitor (HFD Casp.
inh.) group. Each point represents the value of an individual mouse (Control, HFD, HFD_Chow, 
HFD Low Responders, HFD + Rosu t=12/22, HFD + Feno t=12: n=12/group, HFD + Feno t=22 
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Discussion
Obesity is a major risk factor for OA and low grade systemic inflammation associated 
with obesity have been suggested to contribute to the development of OA (4, 8). 
Unraveling the precise mechanism of how obesity influences OA development has the 
potential to find new targets for the development of disease modifying therapies for 
OA. We studied the effects of a HFD on the development of OA in male APOE*3Leiden.
CETP mice, a mouse model with a human-like lipoprotein metabolism. The data in 
this study revealed that after 32 weeks of HFD features of OA were present, however 
less severe than expected. As a matter of fact, OA development in the HFD group 
tended to be lower than in lean mice receiving a chow control diet. As a consequence 
the data of the various treatments are difficult to interpret.
The current study was based on an unpublished study designed for lipid research 
purposes. Herein we found promising results for the APOE*3Leiden.CETP mouse 
as a model for HFD-induced OA. Interestingly, in that experiment treatment for 9 
weeks with fenofibrate significantly suppressed OA grades (HFD 13.4 ± 3.8 vs HFD 
fenofibrate 7.9 ± 5.7, p=0.04), thereby substantiating in vitro observations that 
fenofibrate has the potential to interfere with degenerative and inflammatory 
processes in OA. Unexpectedly, we could not validate these data in the current study. 
We found an overall OA score of 6.0 ± 2.9 in the HFD group which was substantially 
lower than the OA score of 13.4 ± 3.8 found in the HFD group of the lipid study. With 
respect to the in-life parameters BW, plasma cholesterol and TG levels no anomalies 
were observed during the study. Moreover the pilot study, which ran 5 weeks ahead 
of the main study, gave no indication which would explain the lack of effect of HFD on 
OA development. These unexpected results may potentially be explained by several 
observations. At first, although a comparable protocol with regard to strain, length of 
the study, HFD and gender was applied as in the lipid study, the addition of fructose 
to the drinking water was omitted. Addition of fructose to the drinking water results 
in a switch from HDL to ApoB containing lipoprotein ((V)LDL) in the lipoprotein profile 
of APO*3Leiden.CETP mice inducing a more human-like cholesterol distribution (12). 
Fructose consumption in human subjects has been linked to features of the metabolic 





































to the activation of classical inflammatory pathways such as nuclear factor kappa B 
(37). In a previous publication, OA development and progression was accelerated 
in the human C-reactive protein (hCRP) transgenic mice, a translational model to 
monitor inflammation, on HFD (8). As these mice have no VLDL fraction, these data 
suggest that VLDL particles are not contributing to the process of HFD-induced OA. 
The HFD-induced OA mouse model in combination with a fructose component has 
never been investigated (38). At this moment we cannot exclude that fructose water 
is required to induce OA in the APOE*3Leiden.CETP strain in combination with a HFD. 
If the hypothesis that fructose is essential for inducing OA is prospectively validated 
then a highly specific pathway for induction of OA emerges.
Secondly, SAA levels, a marker for inflammation, in the plasma levels collected at 
the start of the study were highly variable. This may have influenced their response 
to the HFD. Whether these highly variable SAA levels could be correlated to the 
lack of OA development 32 weeks later on is uncertain and further research on the 
inflammatory status of these mice is required.
It is remarkable that lean mice on a chow control diet developed more advanced 
OA grades than previously observed in the hCRP mice (9.6 ± 6.0 vs 4.4 ± 2.9) (8). This 
may be attributed to differences in the lipoprotein profile between these strains, 
since the hCRP strain has a wild-type lipoprotein profile with cholesterol mostly 
contained in HDL, and the APOE*3Leiden.CETP strain has a human-like cholesterol 
distribution. To assess for the different lipoprotein profiles on OA development it 
would be very interesting to perform a study in which identical protocols are applied 
to APOE*3Leiden.CETP transgenic mice and their wild type littermates. Mice on a 
control chow diet tended to display even more OA than mice on a HFD. Four mice 
on a control diet developed severe OA while the others developed comparable OA 
grades to the other groups. We do not have an explanation for this cluster forming 
yet and more research is required.
In summary, from unpublished data we can conclude that the male APOE*3Leiden.
CETP mouse strain develops knee OA on a HFD with fructose water and that 
fenofibrates can possibly interfere in this process. However data from the current 
experiment indicate that improved understanding of the used APOE*3Leiden.CETP 
mouse model towards OA development is necessary to understand the outcomes of 
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Osteoarthritis (OA) is a frequently occurring joint disorder with great impact on 
the quality of life. In general, OA is described as a heterogeneous disease with 
degeneration of articular cartilage as main outcome (1-3). Despite extensive research 
on the pathogenesis of OA, there is until now no cure and treatments are primarily 
aimed at reducing pain. The heterogeneity of the patient population might be one 
of the reasons for the absence of appropriate treatments. Although the clinical 
symptoms are the same, i.e. structural damage and symptomatic features such as 
pain, the underlying processes for the development of OA may be different. The 
inclusion of all OA patients, instead of stratification for different types of OA patients, 
may lead to a ‘contamination’ of clinical trials and may explain the observed lack of 
efficacy of candidate drugs. Evidence starts to appear that mild inflammation and 
obesity-related biochemical changes are involved in OA pathology (4). It is uncertain 
what the relative contribution of these processes is and if they characterize a certain 
type of OA patients. By understanding the underlying disease mechanism, having 
a better patient stratification and an improved prediction of disease outcome, the 
efficiency of clinical trials of novel drugs can be optimized. We aim to provide insight 
in the role of multiple local and systemic factors contributing to the pathogenesis of 
OA.
Osteoarthritis as a multiple tissues disease
For a long time, OA research has concentrated on articular cartilage. Nowadays, 
however, a role for other tissues of the joint is appreciated as well (5-7). In the first 
three chapters of this thesis we discuss the possible involvement of multiple knee 
joint tissues in the OA process. One of these tissues is the synovium, which is in direct 
contact with articular cartilage. Increasing evidence indicates that inflammation 
of the synovium contributes to degenerative processes in the cartilage and that 
inflammatory cell types, such as macrophages, present in this tissue may secrete 
factors modifying joint homeostasis (8). In chapter 2 we investigated if the secretion 
of soluble mediators (e.g. cytokines, chemokines, adipokines) is different between 
OA and normal synovial tissue and if OA synovial tissue is able to initiate cartilage 
degradation. Surprisingly, the levels of secreted mediators by OA synovial tissue were 





































excretion of pro-inflammatory cytokines from OA synovial tissue. Moreover, we 
demonstrated that the responsiveness of OA synovial tissue to the pro-inflammatory 
trigger IL-1 was diminished compared to normal. An explanation of these unexpected 
results could be that the OA synovial tissue was derived from end stage OA 
patients. The long-lasting exposure to an inflammatory environment during disease 
progression might have led to ongoing inflammation-resolving mechanisms in the 
synovial tissue of late phase OA patients and may explain why the synovial tissues do 
not respond to a pro-inflammatory trigger anymore (9). Furthermore, we found no 
additional effects of the synovial tissues on the basal release of glycosaminoglycans 
(GAG) from the matrix, nor on the matrix metalloproteinase (MMP) activity, when co-
cultured with cartilage explants. We conclude that synovial tissue from end stage OA 
patients is not or no longer capable of initiating cartilage degradation, however these 
results do not rule out the involvement of synovial tissue in an earlier phase of OA 
development. It should also be noted that the effect of OA and normal synovial tissue 
on OA derived cartilage was not investigated for its role in the progression of OA. 
Other groups have shown that synovitis is correlated with symptom severity, rate of 
cartilage degeneration and osteophytosis (10). However, the synovial response in OA 
is complex and data in literature are contradictory. The data in chapter 2 emphasize 
this complexity, which may be attributed to time-dependent changes in the immune 
response during disease development.
Another neglected tissue in the knee joint is the infrapatellar fat pad (IPFP). This 
special form of adipose tissue is located intracapsularly and extrasynovially in the 
joint (11). The relevance of this joint tissue in the OA process is uncertain, but it is 
hypothesized that IPFP contributes to the development of OA by the secretion of 
inflammatory mediators (12-14). In chapter 3 we examined the secretion of a special 
class of inflammatory mediators, named oxylipins, by the IPFP. These mediators are 
derived from essential fatty acids and are important signaling molecules involved 
in inflammatory processes and the maintenance of physiological processes through 
the whole body (15, 16). With an LC-MS/MS approach, a wide panel of essential 
fatty acids and oxylipins (e.g. prostaglandins) involved in pro-inflammatory and 
inflammation-resolving processes in IPFP-conditioned medium (FCM) was detected. 
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demonstrated that OA FCM could be distinguished from normal FCM with regard 
to the detected essential fatty acids and oxylipins. OA FCM samples obtained with 
the same protocol but at another location revealed comparable error rates for 
OA samples in the PLS-DA model, which strengthened our findings. The observed 
changes were probably specifically due to OA-related alterations instead of basal 
systemic changes, as the increase of essential free fatty acids (precursors) levels were 
not necessarily associated with an increase in precursor-derived oxylipins. Although 
it is tempting to conclude that these changes are causative for OA development, 
it is very plausible that these disturbances occur as a consequence of OA and may 
contribute to the amplification of the disease process only. These data indicate the 
relevance of balanced mechanisms in the joint and provide a valuable tool for further 
research to the role of IPFP in the OA process. 
In chapter 4 we presented a comprehensive overview of soluble mediators (e.g. 
cytokines, chemokines, adipokines) in knee synovial fluid (SF) of OA and normal 
donors. The mediators in SF can be considered as a representative of processes in the 
knee joint as they are in close contact with synovial tissue, IPFP and articular cartilage. 
We showed with multiplex analysis that SF from OA donors contains increased levels 
of mediators, such as macrophage-derived chemokine (MDC), interleukine (IL)-6 and 
‘regulated and normal T cell expressed and secreted chemokine’ (RANTES), compared 
to SF from normal donors, which is in agreement with the increased involvement of 
inflammatory processes in OA. In addition, principal component analysis (PCA), a 
multivariate statistical analysis, indicated various clusters of cytokines that probably 
reflect the involvement of different processes in the joint. We consider this data set 
valuable as a reference for future experiments to study pathophysiological pathways.
The use of more advanced technologies, such as applied in chapters 2-4, 
demonstrated the application of wide screening opportunities of joint tissues, which 
until recently did not gain a lot of attention in OA research, and emphasized the 
involved processes on a very small scale. The strength of these studies is that the 
results obtained with OA donors could be compared to that of normal donors. Tissues 
from normal donors are difficult to obtain and most studies in literature include a 
comparison with rheumatoid arthritis patients to assess for OA specific alterations. 





































and were obtained from OA patients at the end stage of the disease. The data in 
chapter 2 did not support the hypothesis that alterations in synovial tissue of OA 
patients is one of the potential mechanisms that leads to the initiation of cartilage 
degradation. Surprisingly, the synovial tissue obtained from OA patients turned out 
to secrete levels of mediators comparable to normal donors and was less responsive 
to a pro-inflammatory trigger. This makes us consider whether the end-phase of the 
disease is the most representative stage of OA for studying initiation of cartilage 
degeneration. It has been shown that end stage OA synovial tissue exacerbates OA 
features in OA-derived cartilage explants, suggesting its effect in the perpetuation of 
the disease (17). We realize that to study effects of synovial tissue on the initiation of 
cartilage degradation, tissue from an earlier stage would be more representative, but 
in practice this is very hard to obtain. It should be noted that the mediators secreted 
by IPFP and SF, which are described in chapter 3 and 4, are indicative for the end 
stage of the disease as well, but this may be different for earlier stages. Furthermore, 
the tissues may be altered due to ex vivo modifications. The data should therefore be 
interpreted with caution. Nevertheless, we detected differences in synovial tissues, 
IPFP and SF between normal and OA donors, indicating altered mechanisms in OA.
New questions are raised by the data obtained in chapters 2-4. For example, are 
IPFP and synovial tissue primarily active contributors to the OA process or do they 
get inflamed due to alterations in the joint or body? Do modifications of the tissues 
lead to a more pronounced stage of OA or are these modifications just indicative 
for the current state of the joint? Do these different types of tissues interact? Is it 
sufficient to target one of these tissues, or is a multiple target approach needed? To 
provide answers to these questions, additional research is required and we propose 
an integrated approach to study different potential active tissues in the OA process to 
understand the mechanisms and disturbed pathways. An expansion of the number 
of donors is needed for more extensive profiling. This possibly leads to the discovery 
of new targets for drug development. The results in chapter 2-4 are the first steps in 
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Osteoarthritis as a disease of the whole body
With regard to the above mentioned alterations on a local level, we speculated 
whether these changes could be induced by alterations on a systemic level. This 
hypothesis is encouraged by the fact that the metabolic syndrome is getting more 
and more attention in the Western world and is regarded as an instigator for 
several diseases, such as arthritis, cardiovascular diseases and psoriasis (4, 18). 
The metabolic syndrome comprises a profile including a combination of obesity, 
hypercholesterolemia, hypertension, dyslipidemia and impaired glucose tolerance. It 
has been demonstrated that the metabolic syndrome is associated with features of 
OA and, therefore, may be relevant in search for new targets (19-21). Since decades 
it is known that obesity, an important component of the metabolic syndrome, 
is a strong risk factor for the development and the progression of OA. It has been 
argued that the gain of fat mass leads to an increased loading of the knee joint, 
resulting in cartilage degradation. The fact that obese people also have an increased 
risk to develop OA in non-weight bearing joints, gives reason to consider features 
of the metabolic syndrome to be involved (22). This interesting new concept was 
studied in chapter 5. The intake of a high fat diet (HFD) by human c-reactive protein 
(hCRP, a marker for inflammation (23, 24)) transgenic mice led to an increased OA 
development compared to chow-fed control mice, which was not correlated with 
body weight or fat mass. Interventions with rosuvastatin (cholesterol-lowering) and 
rosiglitazone (a peroxisome proliferator-activated receptor (PPAR)-γ agonist, anti-
diabetic) suppressed OA to a level comparable to that of control mice. As these 
drugs have different modes of action, but do have in common that they exert anti-
inflammatory actions, we conclude that low grade inflammation (metabolic stress) 
plays a major role in the development of OA in this mouse model. Additionally, we 
found a correlation between OA grade at end point and the change in hCRP levels 
shortly after the start of the study. Extrapolation of these data to the human situation 
suggests that the responsiveness to a metabolic challenge can be used as a marker 
to estimate the individual susceptibility to develop OA later in life. Therefore, 
correlations between OA development and the metabolic susceptibility of a person 





































In chapter 6 we demonstrated the effect of hypercholesterolemia, another feature 
of the metabolic syndrome, on the development of OA. Several epidemiological 
studies have shown an association between OA and elevated cholesterol levels or 
atherosclerosis (a cardiovascular disease for which elevated cholesterol levels display 
an increased risk of disease development) (25-28). The elevated intake of cholesterol 
has been suggested to cause a certain grade of inflammation in mice and men (29). In 
this study, a dose-dependent effect of the intake of cholesterol on the development 
of OA in female APOE*3Leiden cholesteryl ester transfer protein (CETP) transgenic 
mice (a mouse model which resembles human lipoprotein metabolism, in contrary 
to wild type mice, and develops hyperlipidemia and atherosclerosis (30-32)) was 
observed. A moderate association between OA, cholesterol levels and atherosclerosis 
indicated that cholesterol is involved. However, the data also suggested that other 
processes evoked by the intake of cholesterol are involved in the pathogenesis of OA. 
Indeed, levels of some inflammatory markers were elevated due to the high intake 
of cholesterol in the diet. Again, we demonstrated that statins had a suppressive 
effect on the development of OA features. This cannot be fully subscribed to their 
cholesterol lowering capacities, as ezetimibe treatment (a cholesterol-lowering drug 
with a different mode of action) reduced OA development to a lesser extent while 
its lowering of cholesterol was comparable. Like in chapter 5, there was no role for 
increased mechanical forces due to body weight, as mice receiving cholesterol in 
their diet had body weights comparable to control mice.
In the study in chapter 7, we aimed to better understand the mechanism of HFD-
induced OA. We showed that the intake of a very HFD by male APOE*3LeidenCETP 
mice led to the development of OA, but less severe than expected. Moreover, OA 
progression in the HFD group was even less than in control mice receiving chow diet. 
There were no effects of various interventions on OA development compared to the 
HFD group. We have several indications that can explain these results. The first is 
that there was no fructose in the drinking water, in contrast to a previous study with 
male APOE*3LeidenCETP mice on HFD, which developed severe OA. Fructose leads 
to a shift from HDL (‘good’ cholesterol) to VLDL (‘bad’ cholesterol). The hypothesis 
that a shift in lipoprotein profile is essential for the induction of OA, deserves more 
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OA. Furthermore, serum amyloid A levels (an acute phase protein) in the plasma of 
these mice were highly variable at the start of the study, which may have influenced 
their response to the HFD. An interesting observation in this study is that mice on a 
control diet already developed substantial OA. This gives reason to believe that an 
altered lipoprotein profile, compared to wild type mice, increases the sensitivity of 
these mice to develop OA. 
The susceptibility of male and female mice also needs to be addressed. In general, 
male mice are more prone to develop features of the metabolic syndrome and to 
develop features of OA, which is confirmed in the hCRP mice described in chapter 5 
(33-35). However, female APOE*3Leiden.CETP mice are more susceptible to develop 
high serum cholesterol levels and consequently more features of atherosclerosis 
(chapter 6), which is not observed in their male counterparts, even though they had 
an even higher cholesterol intake (data not shown). Based on these observations, it 
would be interesting to examine the effects of a HFD in combination with cholesterol 
on the development of female APOE*3Leiden.CETP mice. 
In chapters 5 and 6 we demonstrated that features of the metabolic syndrome 
(obesity and hypercholesterolemia) induced the development of OA in mice. The 
low grade systemic inflammation evoked by these metabolic alterations may be 
held responsible for the initiation or progression of OA processes in the joint, but 
we cannot exclude the involvement of other factors. The effects of statins on the 
development of OA in mice contribute to the idea of a beneficial effect of statins in 
human OA. Although limited human data are available, it has been demonstrated 
that the use of statins is associated with a substantial reduction in knee, but not 
hip, OA progression (36). A plausible mode of action for the effect of statins is the 
inhibition of the formation of atherosclerotic plaques, as a consequence of high 
cholesterol exposure, and therewith improving the blood flow of subchondral 
bone. Furthermore, a direct effect on chondrocytes by targeting MMPs (37) is 
suggested. The only moderate correlations between cholesterol levels, features of 
atherosclerosis and the development of OA we found (chapter 6) do not contribute 
to these hypotheses. Based on our data, we propose that the main effect of statins 
can be subscribed to their anti-inflammatory properties, possibly by the inhibition of 





































Unraveling the pathways involved in obesity-associated low-grade systemic 
inflammation leading to OA may reveal new targets for intervention. Adipokines, 
which are secreted by adipose tissues as well as by several joint tissues, may be 
interesting targets. It has been demonstrated that leptin expression is higher in OA 
cartilage than in normal cartilage (38). Furthermore, visfatin, resistin and adiponectin 
levels are associated with features of OA (39). A study in leptin-deficient mice shows 
that these mice become very obese, but do not develop features of OA, indicating 
a possible role of leptin in the development of OA (40). With the knowledge that, 
until now, regular anti-cytokine therapies failed in the treatment of OA, these 
relatively newly discovered adipokines should be considered as promising targets for 
interference. We measured a significant increase in leptin and resistin levels in mice 
fed a HFD compared to mice receiving a control diet (chapter 5). However, these 
levels (measured at end point) were not correlated with the development of OA and 
were not affected by statins or rosiglitazone. This suggests that, if leptin is involved 
in HFD-induced OA, the inhibitory effect of rosuvastatin and rosiglitazone treatments 
is not mediated through direct acting on leptin, but possibly by influencing the 
downstream inflammatory processes that are regulated by leptin.
To link the local (chapters 2-4) and systemic (chapters 5 and 6) alterations on OA 
development, the following model can be proposed (figure 1): the elevated intake 
of, for example, fat or cholesterol in the diet leads to systemic alterations, giving 
rise to features of the metabolic syndrome and resulting in low-grade systemic 
inflammation. Due to the increased release of pro-inflammatory mediators in the 
blood, cells in the different joint tissues are activated and stimulated to secrete 
more pro-inflammatory mediators and/or matrix-degrading enzymes, therewith 
influencing cartilage homeostasis and contributing to OA development. The local 
inflammation and degradation products of cartilage can accordingly amplify the 
inflammatory response. In addition, different features of the metabolic syndrome 
may directly lead to modification of the different joint tissues, for instance by the 
accumulation of lipid droplets in the cells. This proposed paradigm strongly suggests 
considering OA as part of a bigger circle and deserves more investigation in patients 





























































































































































































































































































































































































































































































OA is a frequently occurring disease and multiple factors, such as genetic, 
environmental, mechanical, and diet contribute to the development, progression and 
severity. We identify obesity, high cholesterol and systemic inflammation associated 
with these conditions as major players in OA development, which may activate 
joint tissues to secrete inflammatory mediators and contribute to the initiation and 
progression of OA. Our work suggests that a stratification of OA patients with (features 
of) the metabolic syndrome as underlying mechanism is recommendable, to optimize 
the efficacy of clinical trials. Approaching OA as a disease induced by whole body 
metabolism, and integrating knowledge about different potentially active tissues in 
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Artrose is een ziekte aan de gewrichten die wereldwijd veel voorkomt. In een 
gezonde situatie bedekt een laagje kraakbeen de botten, wat er onder andere 
voor zorgt dat je gewrichten soepel kunnen bewegen. Wanneer er artrose ontstaat 
breekt het kraakbeen langzaam af en dit leidt tot vervelende symptomen zoals 
pijn, stijfheid en problemen met bewegen. Ondanks dat er veel onderzoek wordt 
gedaan naar het ontstaan en de ontwikkeling van artrose, is er tot op heden nog 
geen geschikte behandeling beschikbaar die het ziekteproces kan stoppen of, 
beter nog, kan genezen. Patiënten zijn aangewezen op pijnmedicatie of moeten 
in een ernstiger stadium een knie- of heupvervangende operatie ondergaan. Het 
ziekteproces van artrose verloopt, ondanks vergelijkbare symptomen, niet bij iedere 
patiënt op de zelfde wijze. De ‘heterogeniteit’ van de patiëntenpopulatie kan een 
reden zijn voor de lage effectiviteit die nieuwe kandidaatmedicijnen veelal vertonen 
in klinische studies. Wellicht worden medicijnen ten onrechte afgekeurd, terwijl een 
subgroep van artrosepatiënten er wel baat bij kan hebben. Door het begrijpen van 
het onderliggende mechanisme van artrose, door een betere voorspelling van de 
ziekte te kunnen doen, en door een betere patiëntstratificatie te hebben, zouden 
klinische studies optimaler ingericht kunnen worden. In dit proefschrift onderzoeken 
wij het effect van verschillende factoren die bij kunnen dragen aan het ziekteproces 
van artrose.
Artrose als een ziekte van het gewricht
In de eerste drie hoofdstukken bestuderen wij de rol van verschillende factoren 
in het gewricht (lokale factoren) op het artroseproces. Tot nu toe lag de focus in 
wetenschappelijk onderzoek met betrekking tot artrose vooral op het kraakbeen. 
Veranderingen in andere weefsels in je gewricht zouden echter ook de oorzaak 
kunnen zijn voor het ontstaan (initiatie) of het verergeren (progressie) van artrose. 
Eén van deze weefsels is het synovium. Het synovium zorgt onder andere voor 
de productie van synoviale vloeistof, wat dient als een soort smeerolie van de 
gewrichten. Bij sommige artrosepatiënten komt ontsteking van het synovium voor. 
Er wordt gesuggereerd dat ontstekingsmediatoren (stoffen) die door de cellen in het 





































In hoofdstuk 2 laten we, tegen onze verwachting in, zien dat synoviaal weefsel 
van artrosepatiënten juist minder ontstekingsmediatoren uitscheidt dan synoviaal 
weefsel van gezonde personen. Ook demonstreren wij dat synoviaal weefsel van 
gezonde personen meer reageert op een ontstekingsstimulus dan het synoviaal 
weefsel van artrosepatiënten. Met behulp van een complex kweeksysteem laten wij 
zien dat het synovial weefsel niet in staat is kraakbeenafbraak te initiëren. Echter, 
onze data sluiten niet uit dat synovium wel betrokken is bij de progressie van de 
ziekte. Belangrijk om te weten is dat het synovium van de artrosepatiënten in 
deze studie afkomstig is van patiënten die een knievervangende operatie hebben 
ondergaan en dus in de eindfase van de ziekte zaten. Het synovium was wellicht al 
langdurig blootgesteld aan ontstekingsstimuli en er daardoor aan ‘gewend’ geraakt. 
Dit heeft mogelijk geleid tot de onverwachte uitkomsten in deze studie.
In hoofdstuk 3 kijken wij naar de uitscheiding van ontstekingsmediatoren door 
het infrapatellaire vet. Het infrapatellaire vet is een speciaal soort vetweefsel 
gelegen in het gewricht, dat mogelijk bijdraagt aan het ziekteproces van artrose. 
Wij onderzoeken de uitscheiding van een specifiek soort mediatoren, oxylipines 
en vetzuren, door gezond en artrotisch infrapatellair vetweefsel. De gemeten 
mediatoren zijn statistisch niet verschillend tussen gezond en artrotisch infrapatellair 
vetweefsel. Multivariate analyse (een statische methode waarmee in plaats van 
één, meerdere variabelen worden vergeleken) laat echter zien dat de concentraties 
mediatoren die het infrapatellaire vet uitscheidt wel degelijk een specifiek profiel 
hebben in artrosepatiënten. Met behulp van een zogenaamde ‘pathway analyse’ 
demonstreren wij wáár in de onderliggende mechanismes de verschillen tussen 
gezonde en artrose donoren te detecteren zijn. 
In hoofdstuk 4 laten wij zien welke mediatoren er in de synoviale vloeistof 
van artrose en gezonde donoren zitten. We vinden hogere niveaus van 
ontstekingsmediatoren in synoviale vloeistof van artrosepatiënten ten opzichte van 
gezonde donoren. 
De resultaten in hoofdstuk 2 tot en met 4 suggereren dat niet alleen het kraak-
been, maar ook andere weefsels in het gewricht betrokken zijn in het artroseproces 
en wellicht bijdragen aan de ziekte. Door artrose op deze manier te onderzoeken, 






































stappen zijn gezet, maar er is meer onderzoek nodig om onderliggende mechanisme 
te kunnen begrijpen. 
Artrose als een ziekte van het hele lichaam
In hoofdstuk 2 tot en met 4 onderzoeken wij de bijdrage van lokale factoren in het 
artrose proces. In de hoofdstukken die daarop volgen hebben wij het effect van 
processen die in het hele lichaam plaatsvinden (systemische factoren) bekeken. 
Specifiek hebben wij gekeken naar factoren die associëren met het metabool 
syndroom. Het metabool syndroom is een overkoepelende term voor aandoeningen 
zoals obesitas, diabetes en verstoorde lipiden levels. Het metabool syndroom komt in 
de westerse wereld steeds meer voor en studies hebben laten zien dat mensen met 
het metabool syndroom meer kans hebben op de ontwikkeling van artrose. Hoe dit 
precies komt is nog onduidelijk. Eén van de theorieën is dat het metabool syndroom 
wordt gezien als een aanstichter van ontstekingsprocessen in het lichaam en daardoor 
verschillende ziektes veroorzaakt. In hoofdstuk 5 tot en met 7 hebben wij onderzoek 
gedaan naar de relatie tussen verschillende componenten die geassocieerd worden 
met het metabool syndroom en artrose. Zo hebben wij onder andere gekeken naar 
de invloed van obesitas op de ontwikkeling van artrose. Obesitas wordt gezien als een 
belangrijke risicofactor voor het krijgen van artrose. Lang dachten onderzoekers dat 
de mechanische druk, veroorzaakt door de hoeveelheid vet bij zwaarlijvige mensen, 
hier verantwoordelijk voor is. Er is gebleken dat mensen met obesitas ook meer kans 
hebben op handartrose. Aangezien we niet op onze handen lopen, kunnen we deze 
associatie niet verklaren vanuit de mechanische belasting. De hypothese is daarom 
dat de lage graad van chronische ontsteking die gepaard gaat met obesitas ook 
een rol kan spelen in het ontstaan van artrose. Deze hypothese onderzoeken wij in 
hoofdstuk 5 waarin muizen na het eten van een dieet met veel vet meer artrose laten 
zien dan muizen die een controle dieet te eten krijgen. Wij demonstreren ook dat 
de medicijnen statine (een cholesterol verlager) en rosiglitazone (een anti-diabetica) 
een remmend effect hebben op de ontwikkeling van artrose, ondanks dat deze 
muizen veel zwaarder zijn dan controlemuizen. Beide medicijnen hebben een ander 
werkingsmechanisme, maar gaan allebei ontsteking tegen. Daarnaast laten onze 





































om artrose te ontwikkelen in een later stadium. Als je dit zou vertalen naar de mens, 
zou dat betekenen dat de ‘metabole’ gevoeligheid wel eens voorspellend zou kunnen 
zijn of je artrose ontwikkelt. Hier moeten wij echter nog meer onderzoek naar doen.
In hoofdstuk 6 hebben we de focus gelegd op hypercholesterolemia (te hoge 
cholesterolwaarden in het bloed). Met behulp van speciale muizen, met de bijzondere 
eigenschap dat ze vergelijkbare cholesterol profielen hebben als de mens, kijken wij 
naar het effect van teveel cholesterol in het dieet op de ontwikkeling van artrose 
in de knieën. De muizen laten hele hoge cholesterolwaarden in hun bloed zien en 
ze ontwikkelen, zoals verwacht, heftige atherosclerose (aderverkalking). Wij zien 
dat muizen die een dieet met veel cholesterol ontvangen meer karakteristieken van 
artrose laten zien dan muizen die een controle dieet krijgen. Ook behandelen wij 
muizen met de medicijnen statine en ezetimibe. Deze behandelingen verlagen allebei 
cholesterol (en dus atherosclerose ontwikkeling), maar statine kan, in tegenstelling 
tot ezetimibe, ook ontsteking tegengaan. Wij zien wederom een onderdrukkend 
effect van statine op de ontwikkeling van artrose. De cholesterolwaarden in het 
bloed zijn niet heel sterk geassocieerd met de ontwikkeling van artrose. Wij 
concluderen daarom dat cholesterol in het bloed niet alleen verantwoordelijk is voor 
de ontwikkeling van artrose, maar dat er ook andere factoren geïnduceerd door 
cholesterol, zoals ontsteking, bij betrokken kunnen zijn.
In hoofdstuk 7 proberen wij meer inzicht te krijgen in het mechanisme van het 
ontstaan van artrose gerelateerd aan de inname van een dieet met veel vet. Naar 
aanleiding van goede resultaten in een pilot studie, bestuderen wij twee interventies 
met een statine en een fenofibraat (beide cholesterol verlagend) bij muizen die 
een dieet met veel vet innemen. Deze behandelingen hebben wij zowel vroeg 
(‘profylactisch’) als laat (‘therapeutisch’) gegeven om daarmee te onderzoeken of 
wij ook in een later stadium van artrose het ziekteproces zouden kunnen remmen. 
Daarnaast onderzoeken wij muizen die niet dik worden van een dieet met veel vet, 
muizen die halverwege de studie van een dieet met veel vet naar een normaal dieet 
wisselen, en muizen die een caspase 1 remmer ontvangen (remt de omzetting van 
een mogelijk belangrijke stof in het artroseproces). De positieve controlegroep 
(muizen die alleen een dieet met veel vet ontvangen) laten niet de ernst van artrose 






































niet analyseren. Een mogelijke reden hiervoor kan zijn dat de muizen geen suiker 
in hun water hebben ontvangen (dit leidt tot ‘slechtere’ cholesterolprofielen) in 
tegenstelling tot de muizen in de pilot studie. Daarnaast hebben de muizen in het 
beginstadium al hoge ontstekingsmarkers in hun bloed, wat mogelijk de onverwachte 
resultaten kan verklaren. Meer onderzoek is nodig om dit op te kunnen helderen.
Conclusie
Artrose is een gewrichtsziekte die veel voorkomt en meerdere factoren kunnen 
bijdragen aan de ontwikkeling, progressie en ernst ervan. In deze thesis hebben wij 
obesitas, hoog cholesterol, en daaraan gerelateerde ontsteking geïdentificeerd als 
mogelijk belangrijke spelers in het artrotische ziekteproces. De ontsteking kan op 
zijn beurt lokale weefsels in het gewricht activeren en daarmee de balans verstoren. 
Ons werk suggereert dat een stratificatie van artrosepatiënten, met als onderliggend 
mechanisme het metabool syndroom, kan bijdragen aan het optimaliseren van 
klinische studies. Door artrose als een ziekte vanuit het hele lichaam te bestuderen 
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